

A Cell-based Model of Hemostasis

Thrombosis and Haemostasis

85, 958-965

DOI: [10.1055/s-0037-1615947](https://doi.org/10.1055/s-0037-1615947)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Continuous Infusion of Recombinant Factor VIIa: Continue or not?. Thrombosis and Haemostasis, 2001, 86, 942-944.	1.8	12
3	Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opinion on Investigational Drugs, 2001, 10, 1925-1935.	1.9	31
4	Genetic Evidence That Protease-activated Receptors Mediate Factor Xa Signaling in Endothelial Cells. Journal of Biological Chemistry, 2002, 277, 16081-16087.	1.6	142
5	Aspartic Acid Residues 72 and 75 and Tyrosine-sulfate 73 of Heparin Cofactor II Promote Intramolecular Interactions during Glycosaminoglycan Binding and Thrombin Inhibition. Journal of Biological Chemistry, 2002, 277, 19823-19830.	1.6	26
6	Editorial: Analysis of Platelet Function and Dysfunction â€œ From Pathobiochemistry to Diagnostics â€œ. Laboratoriums Medizin, 2002, 26, 555-556.	0.1	0
7	Structure, Function, and Activation of Coagulation Factor VII. Current Protein and Peptide Science, 2002, 3, 287-299.	0.7	37
8	Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood, 2002, 100, 539-546.	0.6	49
9	Treatment of Bleeding in Patients with Platelet Disorders: Is There a Place for Recombinant Factor VIIa?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 37-40.	0.5	24
10	Antithrombotic Therapy after Myocardial Infarction. New England Journal of Medicine, 2002, 347, 1019-1022.	13.9	45
11	Platelets and Thrombin Generation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1381-1389.	1.1	579
12	Absence of compensatory platelet activation in patients with severe haemophilia, but evidence for a platelet collagen-activation defect. Platelets, 2002, 13, 451-458.	1.1	17
13	The role of platelets in blood coagulationâ€™ effects of platelet agonists and GPIIb/IIIa inhibitors studied by free oscillation rheometry. Thrombosis Research, 2002, 105, 165-172.	0.8	16
14	Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II. Thrombosis Research, 2002, 107, 67-73.	0.8	9
15	Markers of platelet activation and plateletâ€™leukocyte interaction in patients with myeloproliferative syndromes. Thrombosis Research, 2002, 108, 139-145.	0.8	111
16	Overview of anticoagulant drugs for the future. Seminars in Hematology, 2002, 39, 145-157.	1.8	30
17	Platelet antigens. The role of human platelet alloantigens (HPA) in blood transfusion and transplantation. Transplant Immunology, 2002, 10, 165-181.	0.6	88
18	Activation et inhibition de la coagulationÂ: que se passe-t-il en cas de coagulopathie intravasculaire dissÃ©minÃ©e? Activation and inhibition of coagulation.. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2002, 11, 584-590.	0.1	0
19	Coagulation Factor Interaction with Platelets. Thrombosis and Haemostasis, 2002, 88, 179.	1.8	14

#	ARTICLE	IF	CITATIONS
20	Combined Effects of Eptifibatid and Anticoagulants: Differences between LMWH and UH or rH in Thrombin Generation Inhibition but not in Platelet Aggregation Inhibition. <i>Thrombosis and Haemostasis</i> , 2002, 88, 1012-1019.	1.8	5
25	Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 403-410.	2.3	66
26	Remodeling the Blood Coagulation Cascade. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 16, 17-20.	1.0	277
27	Factor Xa-A pleuripotential protease. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 15, 5-9.	1.0	7
28	Acute myocardial infarction: Antithrombotic therapy. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 3-11.	0.4	0
29	Prothrombotic and antithrombotic pathways in acute coronary syndromes. <i>American Journal of Cardiology</i> , 2003, 91, 3-11.	0.7	342
30	Mechanism of Action of Recombinant Activated Factor VII. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2003, 5, 5-10.	0.2	2
31	Arterial thrombosis for the interventional cardiologist: From adhesion molecules and coagulation factors to clinical therapeutics. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 60, 236-246.	0.7	10
32	The blood coagulation system as a molecular machine. <i>BioEssays</i> , 2003, 25, 1220-1228.	1.2	132
33	Identification and characterization of novel salivary thrombin inhibitors from the ixodidae tick, <i>Haemaphysalis longicornis</i> . <i>FEBS Journal</i> , 2003, 270, 1926-1934.	0.2	84
34	Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. <i>Transfusion</i> , 2003, 43, 885-892.	0.8	47
35	Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 263-268.	1.9	109
36	The participation of leukocytes in coagulant reactions. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 464-469.	1.9	37
37	Functional analysis of the EGF-like domain mutations Pro55Ser and Pro55Leu, which cause mild hemophilia B. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 782-790.	1.9	10
38	Acquired Haemophilia: Review and Meta-Analysis Focused on Therapy and Prognostic Factors. <i>British Journal of Haematology</i> , 2003, 121, 21-35.	1.2	400
39	The use of recombinant factor VIIa in children with inherited platelet function disorders. <i>British Journal of Haematology</i> , 2003, 121, 477-481.	1.2	154
40	Oscar ratnoff: his contributions to the golden era of coagulation research. <i>British Journal of Haematology</i> , 2003, 122, 180-192.	1.2	18
41	Activation of platelets in whole blood by recombinant factor VIIa by a thrombin-dependent mechanism. <i>British Journal of Haematology</i> , 2003, 122, 651-661.	1.2	15

#	ARTICLE	IF	CITATIONS
42	A cell-based model of coagulation and the role of factor VIIa. <i>Blood Reviews</i> , 2003, 17, S1-S5.	2.8	244
43	Effects of inhibition of P2Y1 and P2Y12 on whole blood clotting, coagulum elasticity and fibrinolysis resistance studied with free oscillation rheometry. <i>Thrombosis Research</i> , 2003, 109, 315-322.	0.8	16
44	Inflammatory response to cardiopulmonary bypass. <i>Annals of Thoracic Surgery</i> , 2003, 75, S715-S720.	0.7	505
45	Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model. <i>Journal of Hepatology</i> , 2003, 39, 954-959.	1.8	22
46	Idiopathic thrombocytopenic purpura of childhood: A problem-oriented review of the management. <i>Transfusion and Apheresis Science</i> , 2003, 28, 243-248.	0.5	6
47	Influence of Different Anticoagulant Agents on Fibrinopeptide A Generation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 273-292.	0.7	3
48	Transcriptional Regulation of Limulus Factor C. <i>Journal of Biological Chemistry</i> , 2003, 278, 49428-49437.	1.6	12
49	Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2088-2096.	0.4	58
51	Recombinant activated factor VII for the treatment of life-threatening haemorrhage. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 713-717.	0.5	81
52	Novel Applications of Recombinant Factor VIIa for the Management of Pediatric Coagulopathic Diseases. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 499-502.	0.3	19
53	Tissue Factor Pathway Inhibitor in Thrombosis and Beyond. , 2004, 93, 133-156.		13
54	Effect of factor VIII on tissue factor-initiated spatial clot growth. <i>Thrombosis and Haemostasis</i> , 2003, 89, 235-242.	1.8	28
55	Antithrombotic activity of LB30057, a newly synthesized direct thrombin inhibitor. <i>Thrombosis and Haemostasis</i> , 2003, 89, 104-111.	1.8	5
56	Intravascular tissue factor pathway – a model for rapid initiation of coagulation within the blood vessel. <i>Thrombosis and Haemostasis</i> , 2003, 89, 3-8.	1.8	88
57	Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia. <i>Thrombosis and Haemostasis</i> , 2003, 90, 1054-1060.	1.8	22
58	Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. <i>Thrombosis and Haemostasis</i> , 2003, 90, 781-786.	1.8	82
59	Treating Traumatic Bleeding in a Combat Setting: Possible Role of Recombinant Activated Factor VII. <i>Military Medicine</i> , 2004, 169, 16-18.	0.4	33
60	Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1182-1193.	1.8	16

#	ARTICLE	IF	CITATIONS
61	Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - A direct and selective antagonist. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1229-1231.	1.8	1
62	Age- and sex-specific incidence, risk, and latency period of a perioperative acute thromboembolism syndrome (PATS). <i>Thrombosis and Haemostasis</i> , 2004, 91, 725-732.	1.8	19
63	Coagulation, Inflammation, and the Risk of Neonatal White Matter Damage. <i>Pediatric Research</i> , 2004, 55, 541-545.	1.1	93
65	Quantitative Tissue Factor Gene Expression Analysis in Whole Blood: Development and Evaluation of a Real-Time PCR Platform. <i>Clinical Chemistry</i> , 2004, 50, 245-247.	1.5	6
66	A New Mutation (Arg251 Trp) in the Ca ²⁺ Binding Site of Factor X Protease Domain Appears to be Responsible for the Defect in the Extrinsic Pathway Activation of Factor X Padua. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2004, 10, 5-8.	0.7	10
67	Recombinant Activated Factor VII in Patients at High Risk of Bleeding. <i>Hematology</i> , 2004, 9, 317-332.	0.7	22
68	The role of activated recombinant factor VII (rFVIIa) in acute severe bleeding. <i>Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine</i> , 2004, 15, 115-117.	0.1	1
69	FEIBAR: mode of action. <i>Haemophilia</i> , 2004, 10, 3-9.	1.0	165
70	Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 147-153.	1.9	119
71	Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 459-467.	1.9	20
72	Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1096-1103.	1.9	179
73	Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1299-1304.	1.9	22
74	Recombinant FVIIa. <i>Vox Sanguinis</i> , 2004, 87, 25-28.	0.7	5
75	Hemostatic effect of activated recombinant factor VIIa in Bernard-Soulier syndrome: studies in an in vitro model. <i>Transfusion</i> , 2004, 44, 1790-1791.	0.8	6
76	Antidote-mediated control of an anticoagulant aptamer in vivo. <i>Nature Biotechnology</i> , 2004, 22, 1423-1428.	9.4	318
77	The thrombogenic effect of an inflammatory cytokine on trophoblasts from women with preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 191, 2142-2147.	0.7	8
78	The Effect of Temperature Variation In Vitro on Platelet-Leukocyte Interactions and Individual Prothrombotic Potential. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 18, 19-23.	1.0	4
79	Optimizing Heparin Compounds: A Working Construct for Future Antithrombotic Drug Development. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 18, 55-58.	1.0	9

#	ARTICLE	IF	CITATIONS
80	Factor Xa?Protease Activated Receptor Interface: A Paradigm for Combination Pharmacotherapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 18, 153-155.	1.0	1
81	Vascular Endothelial Tissue Factor Pathway Inhibitor Kinetics in Culture Following Exposure to DX-9065aâ€”A Selective and Direct Factor Xa Inhibitor. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 18, 193-197.	1.0	1
82	The search for a unified theory of coagulation and inflammation. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 2744-2749.	2.4	5
83	Coagulation in sepsis. <i>Intensive Care Medicine</i> , 2004, 30, 1032-1040.	3.9	152
84	Fibrinogen receptor antagonists induce conformational changes of the human platelet glycoprotein IIb. <i>Cytometry</i> , 2004, 62B, 14-24.	1.8	4
85	El sistema hemostÃ¡tico en los sÃ¡ndromes coronarios agudos: implicaciones fisiopatolÃ³gicas y terapÃ©uticas. <i>Revista Clinica Espanola</i> , 2004, 204, 221-227.	0.2	2
86	RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. <i>FEBS Letters</i> , 2004, , .	1.3	0
87	Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 661-674.	0.6	13
88	RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. <i>FEBS Letters</i> , 2004, 568, 10-14.	1.3	30
89	A critical role for thrombin in platelet aggregation under high shear stress. <i>Thrombosis Research</i> , 2004, 113, 311-318.	0.8	11
90	P-selectin modulation in haemostasis: one size fits all?. <i>Trends in Molecular Medicine</i> , 2004, 10, 9-12.	3.5	3
91	Thrombin generation assays: accruing clinical relevance. <i>Current Opinion in Hematology</i> , 2004, 11, 170-175.	1.2	101
92	Use of recombinant factor VIIa, Novo Seven, in the management of acute haemorrhage. <i>Current Opinion in Anaesthesiology</i> , 2004, 17, 159-163.	0.9	6
93	Combined effects of melagatran and eptifibatide on platelet aggregation inhibition but not thrombin generation inhibition. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 131-137.	0.5	0
94	Tissue factor. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 521-538.	0.5	41
95	Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 585-596.	0.5	17
96	Major Post-Partum Hemorrhage and Treatment with Recombinant Factor VIIa. <i>Anesthesia and Analgesia</i> , 2005, 101, 1886-1887.	1.1	9
97	Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 145-147.	0.5	9

#	ARTICLE	IF	CITATIONS
98	Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 61-67.	0.5	31
99	Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants. <i>Blood</i> , 2005, 105, 3902-3909.	0.6	30
100	3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 2773-2782.	1.4	25
101	Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2039-2043.	1.9	194
102	Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2245-2253.	1.9	20
103	Effects of anticoagulant treatment on intestinal ischaemia and reperfusion injury in rats. <i>Acta Anaesthesiologica Scandinavica</i> , 2005, 49, 517-524.	0.7	17
104	The measurement and application of thrombin generation. <i>British Journal of Haematology</i> , 2005, 130, 653-661.	1.2	142
105	Circulating microparticles are elevated in haemophiliacs and non-haemophilic individuals aged <18 years. <i>British Journal of Haematology</i> , 2005, 131, 487-489.	1.2	15
106	Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. <i>Liver Transplantation</i> , 2005, 11, 895-900.	1.3	224
107	Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. <i>Liver Transplantation</i> , 2005, 11, 973-979.	1.3	251
108	Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. <i>Annals of Hematology</i> , 2005, 84, 816-822.	0.8	43
109	Patient-Specific Antithrombotic Strategies: Lessons Not Yet Learned from the Renal Insufficiency Paradigm. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 215-217.	1.0	0
110	The Importance of Factor Xa Regulatory Pathways in Vascular Thromboresistance: Focus on Protein Z. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 135-137.	1.0	7
111	Cell-Based Models of Coagulation: A Paradigm in Evolution. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 20, 65-68.	1.0	32
112	Preexisting Morbidity as an Independent Risk Factor for Perioperative Acute Thromboembolism Syndrome. <i>Archives of Surgery</i> , 2005, 140, 1210.	2.3	41
113	Disorders of coagulation. , 2005, , 295-362.		0
114	Role of Thrombogenic Factors in the Development of Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005, 12, 1-8.	0.9	50
115	Rekombinanter Faktor VIIa zur Reduktion des Transfusions -bedarfs bei orthotoper Lebertransplantation â€” eine multizentrische, randomisierte, Placebo-kontrollierte Doppel-Blind-Studie. , 2005, , 267-269.		0

#	ARTICLE	IF	CITATIONS
116	Large deletions of the PROS1 gene in a large fraction of mutation-negative patients with protein S deficiency. <i>Thrombosis and Haemostasis</i> , 2005, 94, 951-957.	1.8	32
117	Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. <i>Thrombosis and Haemostasis</i> , 2005, 94, 958-964.	1.8	130
118	Effect of Hirudin versus Heparin on Hemocompatibility of Blood Contacting Biomaterials: An in Vitro Study. <i>International Journal of Artificial Organs</i> , 2005, 28, 1272-1277.	0.7	22
119	Coagulopathy and blood component transfusion in trauma. <i>British Journal of Anaesthesia</i> , 2005, 95, 130-139.	1.5	237
120	Platelet Function Tests and Flow Cytometry to Monitor Antiplatelet Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 393-399.	1.5	45
121	Modulators of the Coagulation Cascade: Focus and Recent Advances in Inhibitors of Tissue Factor, Factor VIIa and their Complex. <i>Current Medicinal Chemistry</i> , 2005, 12, 397-417.	1.2	32
122	Coagulation under Flow: The Influence of Flow-Mediated Transport on the Initiation and Inhibition of Coagulation. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2005, 34, 91-108.	0.5	105
123	Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs. <i>Veterinary Clinical Pathology</i> , 2005, 34, 389-393.	0.3	139
124	Thrombosis and Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 617-628.	2.4	134
125	Emerging Off-Label Uses for Recombinant Activated Factor VII: Grading the Evidence. <i>Critical Care Clinics</i> , 2005, 21, 611-632.	1.0	30
126	Platelets and tissue factor. <i>Platelets</i> , 2005, 16, 313-319.	1.1	26
127	Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. <i>Critical Care</i> , 2005, 9, S15.	2.5	31
128	Understanding the dynamics of thrombin in cardiovascular disease: Pathobiology and biochemistry for the clinician. <i>American Heart Journal</i> , 2005, 149, S2-S8.	1.2	13
129	Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa. <i>Platelets</i> , 2005, 16, 45-50.	1.1	23
130	Cardiovascular Biomarkers. , 2006, , .		5
131	Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A. <i>Platelets</i> , 2006, 17, 378-384.	1.1	23
132	The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 73-81.	1.4	13
133	The Use of Recombinant-Activated Factor VII to Successfully Control Postoperative Critical Bleeding After Emergency Repair of Ruptured Abdominal Aortic Aneurysm in a Noncoagulopathic Patient. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2006, 20, 570-572.	0.6	2

#	ARTICLE	IF	CITATIONS
134	Tissue Factor Encryption. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 456-461.	1.1	242
135	What Does It Take to Make the Perfect Clot?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 41-48.	1.1	341
136	Spatial Propagation and Localization of Blood Coagulation Are Regulated by Intrinsic and Protein C Pathways, Respectively. <i>Biophysical Journal</i> , 2006, 90, 1489-1500.	0.2	126
137	Coagulation interventions in experimental human endotoxemia. <i>Translational Research</i> , 2006, 148, 263-271.	2.2	30
138	Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. <i>Critical Care</i> , 2006, 10, R104.	2.5	34
139	Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. <i>American Journal of Surgery</i> , 2006, 191, 245-249.	0.9	89
140	Perioperative Management of the Patient with Hematologic Disorders. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2006, 18, 161-171.	0.4	4
141	Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. <i>Thrombosis Research</i> , 2006, 117, 439-446.	0.8	21
144	Hematological processes in emboli formation. , 2006, , 45-58.		0
146	Translational vehicles for neuroprotection. <i>Biochemical Society Transactions</i> , 2006, 34, 1318-1322.	1.6	6
147	Cutaneous wound healing is impaired in hemophilia B. <i>Blood</i> , 2006, 108, 3053-3060.	0.6	104
148	The Place of Recombinant Activated Factor VII in Liver Transplantation. <i>International Anesthesiology Clinics</i> , 2006, 44, 99-110.	0.3	10
149	KEY ISSUES IN ADVANCED BLEEDING CARE IN TRAUMA. <i>Shock</i> , 2006, 26, 322-331.	1.0	137
151	Proposed structural models of the prothrombinase (FXa-FVa) complex. <i>Proteins: Structure, Function and Bioinformatics</i> , 2006, 63, 440-450.	1.5	47
152	Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 372-376.	1.9	16
153	Inhibition of PAR4 Signaling Mediates Ethanol-Induced Attenuation of Platelet Function In Vitro. <i>Alcoholism: Clinical and Experimental Research</i> , 2006, 30, 1608-1614.	1.4	12
154	Recombinant Factor VIIa: A Review on Its Clinical Use. <i>International Journal of Hematology</i> , 2006, 83, 126-138.	0.7	24
155	Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2006, 85, 1239-1247.	1.3	35

#	ARTICLE	IF	CITATIONS
156	Recombinant factor VIIa use in patients with the rarest forms of inherited coagulation-factor deficiencies: a study of cases from the www.haemostasis.com registry. <i>Comparative Clinical Pathology</i> , 2006, 15, 203-210.	0.3	0
157	Recombinant Factor VIIa for Life-Threatening Hemorrhage in Trauma Patients: Review of the Literature. <i>European Journal of Trauma and Emergency Surgery</i> , 2006, 32, 439-448.	0.3	4
158	Coagulation cascade. <i>Hemodialysis International</i> , 2006, 10, S2-S4.	0.4	63
159	Effects of Cardiac Surgery on Hemostasis. <i>Transfusion Medicine Reviews</i> , 2006, 20, 230-241.	0.9	718
161	Functional Analysis of the Factor IX Epidermal Growth Factor-Like Domain Mutation Ile66Thr Associated with Mild Hemophilia B. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 370-375.	0.5	2
162	Aspirin-Use Before ICH. <i>Stroke</i> , 2006, 37, 4-5.	1.0	12
163	Long-term anticoagulant therapy in patients with coronary artery disease. <i>European Heart Journal</i> , 2006, 27, 913-919.	1.0	23
165	Coagulation and Sepsis. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2006, 6, 175-182.	0.6	13
166	The role of recombinant activated factor VII in neurosurgery: hope or hype?. <i>Journal of Neurosurgery</i> , 2006, 105, 859-868.	0.9	15
167	Recombinant activated factor VII in the treatment of near-fatal bleeding during pediatric brain tumor surgery. <i>Journal of Neurosurgery: Pediatrics</i> , 2006, 104, 55-58.	0.8	13
168	Implementing guidelines for the institutional use of factor VIIa (recombinant): A multidisciplinary solution. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1641-1646.	0.5	12
169	Recombinant Factor VIIA, its Clinical Properties, and the Tissue Factor Pathway of Coagulation. <i>Mini-Reviews in Medicinal Chemistry</i> , 2006, 6, 1111-1117.	1.1	1
170	Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 293.	3.8	610
171	Factor VIII is a positive regulator of platelet function. <i>Platelets</i> , 2006, 17, 448-453.	1.1	8
172	Endothelial cells as active participants in veterinary infections and inflammatory disorders. <i>Animal Health Research Reviews</i> , 2007, 8, 47-58.	1.4	11
173	rFVIIa in trauma: a review and opinion-based guidelines. <i>Trauma</i> , 2007, 9, 237-243.	0.2	1
174	Treatment with anti-factor VIIa in acute pancreatitis in rats: Blocking both coagulation and inflammation?. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 765-770.	0.6	12
175	Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency. <i>Hematology</i> , 2007, 12, 55-62.	0.7	31

#	ARTICLE	IF	CITATIONS
176	Protein C and Its inhibitor in Malignancy. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 667-672.	1.5	30
178	Anticoagulant therapy in acute coronary syndromes. <i>Future Cardiology</i> , 2007, 3, 301-308.	0.5	0
179	Recent Advances in Serine Protease Inhibitors as Anticoagulant Agents. <i>Current Pharmaceutical Design</i> , 2007, 13, 287-312.	0.9	26
180	Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 1-7.	0.5	15
181	Collagen/endogenous thrombin-induced platelet aggregation in whole blood samples. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 585-588.	0.5	10
182	Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates. <i>Thrombosis Research</i> , 2007, 119, 121-127.	0.8	16
183	The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients. <i>Thrombosis Research</i> , 2007, 119, 723-729.	0.8	27
184	The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT. <i>Thrombosis Research</i> , 2007, 119, 361-367.	0.8	12
185	Activation of blood coagulation in patients with major depressive disorder during euglycemic hyperinsulinemia. <i>Thrombosis Research</i> , 2007, 120, 517-521.	0.8	6
186	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007, 28, 880-913.	1.0	119
187	Theories of Blood Coagulation. <i>Journal of Pediatric Oncology Nursing</i> , 2007, 24, 123-131.	1.5	96
188	Management of bleeding following major trauma: a European guideline. <i>Critical Care</i> , 2007, 11, R17.	2.5	352
189	Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial. <i>Critical Care</i> , 2007, 11, R85.	2.5	36
190	Cardiovascular Manifestations of Hypereosinophilic Syndromes. <i>Immunology and Allergy Clinics of North America</i> , 2007, 27, 457-475.	0.7	272
191	Simultaneous Generation of Aptamers to Multiple Gamma-Carboxyglutamic Acid Proteins from a Focused Aptamer Library Using DeSELEX and Convergent Selection. <i>Oligonucleotides</i> , 2007, 17, 1-11.	2.7	59
192	Coagulation 2006: A Modern View of Hemostasis. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1-11.	0.9	219
193	Interactions Between Platelets and the Coagulation System. , 2007, , 377-402.		10
194	Value of Platelet Activation Markers as Prothrombotic Risk Indicators. <i>Transfusion Medicine and Hemotherapy</i> , 2007, 34, 34-42.	0.7	11

#	ARTICLE	IF	CITATIONS
195	Bleeding, Hemostasis, and Transfusion Medicine. , 2007, , 437-460.		6
196	Successful coronary artery bypass graft surgery in severe congenital factor VII deficiency: Perioperative treatment with factor VII concentrate. Thrombosis and Haemostasis, 2007, 98, 900-902.	1.8	14
197	Menorrhagia due to abnormalities of the platelet function: Evaluation of two young patients. Pediatrics International, 2007, 49, 106-108.	0.2	6
198	A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia, 2007, 13, 527-532.	1.0	40
199	Platelets interact with tissue factor immobilized on surfaces: effects of shear rate. European Journal of Clinical Investigation, 2008, 38, 34-42.	1.7	6
200	The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. Journal of Thrombosis and Haemostasis, 2007, 5, 1097-1105.	1.9	130
201	Factor Xa or thrombin: is factor Xa a better target?. Journal of Thrombosis and Haemostasis, 2007, 5, 60-64.	1.9	150
202	Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus. Journal of Thrombosis and Haemostasis, 2007, 5, 1756-1765.	1.9	70
203	Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. Journal of Thrombosis and Haemostasis, 2007, 5, 1577-1583.	1.9	44
204	Essentials of anticoagulation in hemodialysis. Hemodialysis International, 2007, 11, 178-189.	0.4	134
205	Causes and Consequences of Critical Bleeding and Mechanisms of Blood Coagulation. Pharmacotherapy, 2007, 27, 45S-56S.	1.2	34
206	Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Experimental Cell Research, 2007, 313, 677-687.	1.2	60
207	Tissue factor in thrombosis and hemorrhage. Surgery, 2007, 142, S2-S14.	1.0	32
208	Factor VIII-Mediated Global Hemostasis in the Absence of von Willebrand Factor. International Journal of Hematology, 2007, 85, 397-402.	0.7	4
209	New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction. Current Cardiology Reports, 2007, 9, 289-297.	1.3	3
215	Cellular, hemostatic, and inflammatory parameters of the surgical stress response in pigs undergoing partial pericardectomy via open thoracotomy or thoracoscopy. Surgical Endoscopy and Other Interventional Techniques, 2007, 21, 785-792.	1.3	13
216	Pharmacology and clinical use of recombinant activated factor seven in neurosciences. Neurocritical Care, 2007, 6, 149-157.	1.2	9
217	Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000). International Journal of Laboratory Hematology, 2008, 30, 261-268.	0.7	4

#	ARTICLE	IF	CITATIONS
218	Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2008, 48, 12-16.	0.4	91
219	Heparan sulfates from arteries and veins differ in their antithrombin-mediated anticoagulant activity. Journal of Thrombosis and Haemostasis, 2008, 6, 1987-1990.	1.9	14
220	Thrombin generation assay in a patient with acquired factor V inhibitor. Journal of Thrombosis and Haemostasis, 2008, 6, 1985-1987.	1.9	4
221	Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register. Internal Medicine Journal, 2008, 38, 156-165.	0.5	55
222	Successful management by recombinant activated factor VII in a case of disseminated intravascular coagulopathy caused by obstetric hemorrhage. Journal of Obstetrics and Gynaecology Research, 2008, 34, 623-630.	0.6	17
223	Thrombin generation testing in routine clinical practice: are we there yet?. British Journal of Haematology, 2008, 142, 889-903.	1.2	189
224	Applicability and safety of recombinant activated factor VII to control non-chaemophilic haemorrhage: investigational experience in 265 children. Haemophilia, 2008, 14, 753-762.	1.0	20
225	Management of surgery-associated bleeding in cancer patients. Current Anaesthesia and Critical Care, 2008, 19, 59-69.	0.3	2
226	Phospholipid content, expression and support of thrombin generation of neonatal platelets. Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 251-255.	0.7	20
227	Evidence for the Use of Recombinant Factor VIIa in the Prevention and Treatment of Bleeding in Patients Without Hemophilia. Transfusion Medicine Reviews, 2008, 22, 177-187.	0.9	23
228	Haematological management of obstetric haemorrhage. Obstetrics, Gynaecology and Reproductive Medicine, 2008, 18, 265-271.	0.1	4
229	Elevaci3n persistente del d3mero D en el posparto. Medicina Cl3nica, 2008, 131, 478.	0.3	0
230	Novel 3-Carboxamide-coumarins as Potent and Selective FXIIa Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 3077-3080.	2.9	86
231	Recombinant Activated Factor VII in Cardiac Surgery: Experience From the Australian and New Zealand Haemostasis Registry. Annals of Thoracic Surgery, 2008, 85, 836-844.	0.7	59
232	Beyond cell based models of coagulation: Analyses of coagulation with clot lifespan resistance-time relationships. Thrombosis Research, 2008, 122, 145-152.	0.8	42
233	Regulation of tissue factor procoagulant activity by post-translational modifications. Thrombosis Research, 2008, 122, 831-837.	0.8	28
234	Thromboelastographic Evaluation of Hemostatic Function in Dogs with Disseminated Intravascular Coagulation. Journal of Veterinary Internal Medicine, 2008, 22, 357-365.	0.6	161
236	Some things I thought I knew about tissue factor that turn out to be wrong. Thrombosis Research, 2008, 122, S73-S77.	0.8	6

#	ARTICLE	IF	CITATIONS
237	Understanding the therapeutic action of recombinant factor VIIa in platelet disorders. <i>Platelets</i> , 2008, 19, 571-581.	1.1	19
238	Design, Structure-Activity Relationships, X-ray Crystal Structure, and Energetic Contributions of a Critical P1 Pharmacophore: 3-Chloroindole-7-yl-Based Factor Xa Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7541-7551.	2.9	33
239	Crystal structure of an RNA aptamer bound to thrombin. <i>Rna</i> , 2008, 14, 2504-2512.	1.6	135
240	Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. <i>Critical Care</i> , 2008, 12, R14.	2.5	31
241	Effects of heat on camel platelet structure and function—a comparative study with humans. <i>Platelets</i> , 2008, 19, 163-171.	1.1	22
242	Orthostatic Hypercoagulability. <i>Hypertension</i> , 2008, 51, 1545-1551.	1.3	49
243	Will Warfarin Soon Be Passed? New Approaches to Stroke Prevention in Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 52, 18-27.	0.8	15
244	Improved Clot Formation by Combined Administration of Activated Factor VII (NovoSeven®) and Fibrinogen (Haemocomplettan® P). <i>Anesthesia and Analgesia</i> , 2008, 106, 732-738.	1.1	66
245	The Nature of the Stable Blood Clot Procoagulant Activities. <i>Journal of Biological Chemistry</i> , 2008, 283, 9776-9786.	1.6	41
246	Diagnosis and treatment of peripartum bleeding. <i>Journal of Perinatal Medicine</i> , 2008, 36, 467-78.	0.6	58
247	Coagulopathy in trauma: optimising haematological status. <i>Trauma</i> , 2008, 10, 109-123.	0.2	12
248	Novel Considerations in the Pathogenesis of the Antiphospholipid Syndrome: Involvement of the Tissue Factor Pathway of Blood Coagulation. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 251-255.	1.5	14
249	Hemostasis and Thrombosis in Critically Ill Children. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 451-458.	1.5	31
250	Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2008, 112, 4061-4068.	0.6	136
251	FVIIa: you've come a long way, baby!. <i>Blood</i> , 2008, 112, 3002-3003.	0.6	4
252	Pharmacological Strategies for Inhibition of Thrombin Activity. <i>Current Pharmaceutical Design</i> , 2008, 14, 1152-1175.	0.9	63
253	Screening Haemostasis — Looking for Global Assays: The Overall Haemostasis Potential (OHP) Method — A Possible Tool for Laboratory Investigation of Global Haemostasis in Both Hypo- and Hypercoagulable Conditions. <i>Current Vascular Pharmacology</i> , 2008, 6, 173-185.	0.8	19
254	Differential Effects of Factor IIa Inhibitors on the Endogenous Thrombin Potential. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 740-743.	1.0	5

#	ARTICLE	IF	CITATIONS
255	Lepirudin in the management of patients with heparin-induced thrombocytopenia. <i>Biologics: Targets and Therapy</i> , 2008, 2, 481.	3.0	17
256	Hemostatic therapy for intracerebral hemorrhage. , 2009, , 238-253.		1
257	M118 â€“ A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2009, 102, 900-906.	1.8	12
258	Amniotic fluid embolism: The complication of known pathomechanism but without pathogenetic therapy?. <i>Thrombosis and Haemostasis</i> , 2009, 101, 795-796.	1.8	9
259	Impacto da utilizaÃ§Ã£o do rFVIIa nas hemorragias intracranianas: RevisÃ£o da literatura. <i>Brazilian Neurosurgery</i> , 2009, 28, 103-108.	0.0	0
260	An Updated Concept of Coagulation With Clinical Implications. <i>Journal of the American Dental Association</i> , 2009, 140, 567-574.	0.7	24
261	Approach to the Patient with an Inherited Bleeding Disorder. , 0, , 1-11.		1
262	Assessment of Thrombin Generation: Useful or Hype?. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 104-110.	1.5	34
264	Safety and Efficacy of Recombinant Activated Factor VII. <i>Circulation</i> , 2009, 120, 21-27.	1.6	281
265	Haemostasis. <i>Medicine</i> , 2009, 37, 133-136.	0.2	14
266	Tissue factor activated thromboelastography correlates to clinical signs of bleeding in dogs. <i>Veterinary Journal</i> , 2009, 179, 121-129.	0.6	95
267	Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 366-380.	1.0	24
268	Perioperative Use of Recombinant Factor VII to Prevent Intraoperative Aneurysm Rupture in High Risk Patients: A Preliminary Safety Evaluation. <i>Neurocritical Care</i> , 2009, 10, 55-60.	1.2	14
270	Thrombin generation assay: a useful routine checkâ€“up tool in the management of patients with haemophilia?. <i>Haemophilia</i> , 2009, 15, 290-296.	1.0	29
271	Thrombin generation and platelet activation induced by rFVIIa (NovoSeven [®]) and NN1731 in a reconstituted cellâ€“based model mimicking haemophilia conditions. <i>Haemophilia</i> , 2009, 15, 1318-1326.	1.0	8
272	Is D-dimer helpful in evaluating stroke patients? A systematic review. <i>Acta Neurologica Scandinavica</i> , 2009, 119, 141-150.	1.0	84
273	Recombinant factor VIIa and fibrinogen display additive effect during <i>in vitro</i> haemodilution with crystalloids. <i>Acta Anaesthesiologica Scandinavica</i> , 2009, 53, 332-338.	0.7	11
274	The treatment of bleeding is to stop the bleeding! Treatment of traumaâ€“related hemorrhage. <i>Transfusion</i> , 2009, 49, 240S-7S.	0.8	27

#	ARTICLE	IF	CITATIONS
275	Clinical guidelines and off-license recombinant activated factor X , VII : content, use, and association with patient outcomes. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 2016-2022.	1.9	7
276	Pulmonary thromboembolism. <i>Journal of Veterinary Emergency and Critical Care</i> , 2009, 19, 30-52.	0.4	75
277	Systemic alterations of bovine hemostasis due to <i>Rhipicephalus (Boophilus) microplus</i> infestation. <i>Research in Veterinary Science</i> , 2009, 86, 56-62.	0.9	58
278	Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?. <i>Pharmacological Research</i> , 2009, 59, 160-166.	3.1	50
280	Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2009, 22, 672-687.	0.7	51
281	Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue. <i>British Journal of Haematology</i> , 2009, 144, 99-106.	1.2	14
282	The Coagulation Cascade in Cirrhosis. <i>Clinics in Liver Disease</i> , 2009, 13, 1-9.	1.0	62
283	The FLAMES Score Accurately Predicts Mortality Risk in Burn Patients (Gomez M, et al. 2008). <i>Journal of Trauma</i> , 2009, 67, 415.	2.3	8
284	Transfusion strategies in postinjury coagulopathy. <i>Current Opinion in Anaesthesiology</i> , 2009, 22, 289-298.	0.9	59
285	Eosinophil Count Probably Not Useful At All in Postsurgical Septic Shock Patients. <i>Journal of Trauma</i> , 2009, 67, 418.	2.3	1
286	The Effects of Fibrinogen Levels on Thromboelastometric Variables in the Presence of Thrombocytopenia. <i>Anesthesia and Analgesia</i> , 2009, 108, 751-758.	1.1	267
287	Re: Transcatheter Arterial Embolization for Pelvic Fractures May Potentially Cause a Triad of Sequela: Gluteal Necrosis, Rectal Necrosis, and Lower Limb Paresis. <i>Journal of Trauma</i> , 2009, 67, 416-417.	2.3	1
288	Do Conventional Treatments of Severe Traumatic Head Injury Worsen Outcome?. <i>Journal of Trauma</i> , 2009, 67, 415-416.	2.3	3
289	The Emerging Role of Rapid Thromboelastography in Trauma Care. <i>Journal of Trauma</i> , 2009, 67, 417-418.	2.3	20
290	RECENT ADVANCES IN HAEMOSTASIS AND THROMBOSIS. <i>Retina</i> , 2009, 29, 1-7.	1.0	45
291	Thiopental Inhibits Lipopolysaccharide-Induced Tissue Factor Expression. <i>Anesthesia and Analgesia</i> , 2009, 109, 109-113.	1.1	15
292	Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. <i>Haematologica</i> , 2009, 94, 1520-1527.	1.7	74
293	Blood Coagulation: Hemostasis and Thrombin Regulation. <i>Anesthesia and Analgesia</i> , 2009, 108, 1433-1446.	1.1	281

#	ARTICLE	IF	CITATIONS
294	Coagulopathy by Hypothermia and Acidosis: Mechanisms of Thrombin Generation and Fibrinogen Availability. <i>Journal of Trauma</i> , 2009, 67, 202-209.	2.3	170
295	Postintubation Hypotension: The "Etomidate Paradox", <i>Journal of Trauma</i> , 2009, 67, 417.	2.3	0
296	Anesthetic concerns for patients with coagulopathy. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 400-405.	0.9	5
297	Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 568-576.	0.5	26
298	Postinjury Coagulopathy Management. <i>Annals of Surgery</i> , 2010, 251, 604-614.	2.1	195
299	Multidisciplinary Approach to the Challenge of Hemostasis. <i>Anesthesia and Analgesia</i> , 2010, 110, 354-364.	1.1	142
300	The Use of Recombinant Activated FVII in Postpartum Hemorrhage. <i>Clinical Obstetrics and Gynecology</i> , 2010, 53, 219-227.	0.6	131
301	In Normal Controls, Both Age and Gender Affect Coagulability as Measured by Thrombelastography. <i>Anesthesia and Analgesia</i> , 2010, 110, 987-994.	1.1	86
302	Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 354-362.	0.5	13
303	Educational Initiative on Critical Bleeding in Trauma: Chicago, July 11-13, 2008. <i>Journal of Trauma</i> , 2010, 68, 225-230.	2.3	27
304	Acute Epidural Hematoma in a Patient With Glanzmann's Thrombasthenia -Case Report-. <i>Neurologia Medico-Chirurgica</i> , 2010, 50, 928-930.	1.0	5
305	Thromboprophylaxis for trauma patients. , 2010, 2010, .		4
306	Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. <i>Blood</i> , 2010, 116, 693-701.	0.6	70
307	Primary Fibrinolysis Is Integral in the Pathogenesis of the Acute Coagulopathy of Trauma. <i>Annals of Surgery</i> , 2010, 252, 434-444.	2.1	270
309	Pathophysiology and Treatment of Coagulopathy in Massive Hemorrhage and Hemodilution. <i>Anesthesiology</i> , 2010, 113, 1205-1219.	1.3	279
311	Perioperative ischemic stroke in non-cardiovascular surgery patients. <i>Journal of Anesthesia</i> , 2010, 24, 733-738.	0.7	38
312	Haemostasis. <i>Surgery</i> , 2010, 28, 530-535.	0.1	6
313	Progressive postinjury thrombocytosis is associated with thromboembolic complications. <i>Surgery</i> , 2010, 148, 667-675.	1.0	28

#	ARTICLE	IF	CITATIONS
314	Thromboelastography results on citrated whole blood from clinically healthy cats depend on modes of activation. <i>Acta Veterinaria Scandinavica</i> , 2010, 52, 38.	0.5	51
315	Regional anaesthesia and anticoagulation. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2010, 24, 121-131.	1.7	22
316	Activated recombinant factor VII (rFVIIa). <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2010, 24, 95-106.	1.7	18
317	Platelet transfusions: the science behind safety, risks and appropriate applications. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2010, 24, 65-83.	1.7	52
318	Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2523-2529.	1.9	34
319	S-nitrosothiols as selective antithrombotic agents – possible mechanisms. <i>British Journal of Pharmacology</i> , 2010, 159, 1572-1580.	2.7	18
320	Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa. <i>Haemophilia</i> , 2010, 16, 290-295.	1.0	14
321	Anticoagulação em pacientes hospitalizados. <i>Medicina</i> , 2010, 43, 107-117.	0.0	0
323	Anticoagulation. , 2010, , 443-451.		1
324	Hydration does not prevent orthostatic hypercoagulability. <i>Thrombosis and Haemostasis</i> , 2010, 103, 284-290.	1.8	9
325	Tissue factor inhibition: Another approach reducing thrombosis after vascular injury. <i>Thrombosis and Haemostasis</i> , 2010, 103, 7-8.	1.8	3
326	Update on Rivaroxaban. <i>Clinical Medicine Blood Disorders</i> , 2010, 3, CMBD.S5101.	0.2	1
327	Tissue Factor and Thrombosis Models. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 900-908.	1.1	40
328	Molecular Intercommunication between the Complement and Coagulation Systems. <i>Journal of Immunology</i> , 2010, 185, 5628-5636.	0.4	605
329	Topical Recombinant Human Thrombin in Surgical Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 477-484.	1.5	38
330	Overview of Anticoagulant Activity of Sulfated Polysaccharides from Seaweeds in Relation to their Structures, Focusing on those of Green Seaweeds. <i>Current Medicinal Chemistry</i> , 2010, 17, 2503-2529.	1.2	60
331	Global Hemostasis: New Approaches to Patient Diagnosis and Treatment Monitoring. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 695-698.	1.5	3
332	Thromboelastography in Veterinary Medicine. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 747-756.	1.5	66

#	ARTICLE	IF	CITATIONS
333	Correction of Coagulopathy for Percutaneous Interventions. <i>Seminars in Interventional Radiology</i> , 2010, 27, 338-347.	0.3	5
334	Coagulation Abnormalities in the Trauma Patient: The Role of Point-of-Care Thromboelastography. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 723-737.	1.5	126
335	Management of bleeding following major trauma: an updated European guideline. <i>Critical Care</i> , 2010, 14, R52.	2.5	694
336	Task-Oriented Modular Decomposition of Biological Networks: Trigger Mechanism in Blood Coagulation. <i>Biophysical Journal</i> , 2010, 98, 1751-1761.	0.2	44
337	Clinical aspects of coagulation. <i>Anaesthesia and Intensive Care Medicine</i> , 2010, 11, 195-199.	0.1	6
338	Lonomia obliqua venom: In vivo effects and molecular aspects associated with the hemorrhagic syndrome. <i>Toxicon</i> , 2010, 56, 1103-1112.	0.8	27
339	Peri-operative diagnosis and treatment of platelet disorders. <i>Southern African Journal of Anaesthesia and Analgesia</i> , 2010, 16, 55-56.	0.1	0
340	A novel ultrasound-based method to evaluate hemostatic function of whole blood. <i>Clinica Chimica Acta</i> , 2010, 411, 106-113.	0.5	39
341	Adaptive force sonorheometry for assessment of whole blood coagulation. <i>Clinica Chimica Acta</i> , 2010, 411, 638-644.	0.5	22
342	Platelet binding and activity of recombinant factor VIIa. <i>Thrombosis Research</i> , 2010, 125, S16-S18.	0.8	13
343	Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats. <i>Thrombosis Research</i> , 2010, 126, 124-129.	0.8	15
344	Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven [®]) therapy in haemophilia a patients. <i>Thrombosis Research</i> , 2010, 126, 144-149.	0.8	39
345	Lonomia obliqua caterpillar envenomation causes platelet hypoaggregation and blood incoagulability in rats. <i>Toxicon</i> , 2010, 55, 33-44.	0.8	26
346	Application of thrombelastography/thromboelastometry to veterinary medicine. <i>Veterinary Clinical Pathology</i> , 2010, 39, 405-416.	0.3	99
347	Regulation of Hemostasis and Thrombosis. , 2010, , 87-95.		0
348	Haemostatically active proteins in snake venoms. <i>Toxicon</i> , 2011, 57, 627-645.	0.8	193
349	<sc>H</sc>emostasis, coagulation, and complications. <i>Endodontic Topics</i> , 2011, 24, 4-25.	0.5	6
350	Cell-ECM Interactions in Repair and Regeneration. , 2011, , 19-65.		8

#	ARTICLE	IF	CITATIONS
351	Hemostasis. , 2011, , 473-490.		2
352	Structure of fibrin network of two abnormal fibrinogens with mutations in the Î±C domain on the human dermal microvascular endothelial cells 1. Blood Coagulation and Fibrinolysis, 2011, 22, 706-711.	0.5	3
353	Venous Valvular Stasisâ€“Associated Hypoxia and Thrombosis: What Is the Link?. Annual Review of Physiology, 2011, 73, 527-545.	5.6	145
354	Rethinking platelet function: Thrombocytopenia induced immunodeficiency in critical illness. Medical Hypotheses, 2011, 77, 798-802.	0.8	21
355	Invited commentary. Journal of Vascular Surgery, 2011, 53, 1037-1038.	0.6	0
356	Tissue Factor/ FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1). Thrombosis Research, 2011, 127, 141-148.	0.8	29
357	Comparative Hemostasis: Animal Models and New Hemostasis Tests. Clinics in Laboratory Medicine, 2011, 31, 139-159.	0.7	18
358	Alternatives to Warfarin-The Next Generation of Anticoagulants. Cardiovascular Therapeutics, 2011, 29, e80-e88.	1.1	9
359	Fibrinogen Availability and Coagulation Function after Hemorrhage and Resuscitation in Pigs. Molecular Medicine, 2011, 17, 757-761.	1.9	18
360	Hemostatic Disorders. , 2011, , 378-418.		0
361	Markers of Coagulation Activation after Hepatic Resection for Cancer: Evidence of Sustained Upregulation of Coagulation. Anaesthesia and Intensive Care, 2011, 39, 847-853.	0.2	19
362	Hypocoagulability, Hypercoagulability and the Interpretation of â€“Normalâ€™ Kaolin-Activated Thrombelastographs in the Perioperative Period. Anaesthesia and Intensive Care, 2011, 39, 802-803.	0.2	4
363	Novos anticoagulantes em cuidados intensivos. Revista Brasileira De Terapia Intensiva, 2011, 23, 68-77.	0.1	4
364	Tissue factor and factor VIIa cross-species compatibility. Frontiers in Bioscience - Landmark, 2011, 16, 3196.	3.0	16
365	Characterisation of factor IX with a glycine-to-valine missense mutation at residue 190 in a patient with severe haemophilia B. Thrombosis and Haemostasis, 2011, 105, 616-625.	1.8	1
366	Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIb on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thrombosis and Haemostasis, 2011, 106, 344-352.	1.8	83
367	The influence of platelets, plasma and red blood cells on functional haemostatic assays. Blood Coagulation and Fibrinolysis, 2011, 22, 167-175.	0.5	80
368	Rapid Thrombelastography Delivers Real-Time Results That Predict Transfusion Within 1 Hour of Admission. Journal of Trauma, 2011, 71, 407-417.	2.3	196

#	ARTICLE	IF	CITATIONS
369	Trauma, Shock, and Disseminated Intravascular Coagulation. <i>Annals of Surgery</i> , 2011, 254, 10-19.	2.1	149
370	Mechanistic Links in Trauma-Induced Coagulopathy. <i>Annals of Surgery</i> , 2011, 254, 20-21.	2.1	7
371	Identifying and improving unreliable items in registries through data auditing. <i>International Journal for Quality in Health Care</i> , 2011, 23, 317-323.	0.9	15
372	Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. <i>Blood</i> , 2011, 118, 2589-2598.	0.6	155
373	Differential Roles of Fibrinogen and von Willebrand Factor on Clot Formation and Platelet Adhesion in Reconstituted and Immune Thrombocytopenia. <i>Anesthesia and Analgesia</i> , 2011, 112, 1034-1040.	1.1	15
374	Principles of hemostasis in children: models and maturation. <i>Paediatric Anaesthesia</i> , 2011, 21, 3-9.	0.6	69
375	Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1825-1834.	1.9	48
376	Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2251-2261.	1.9	153
377	Determination of canine coagulation factor VII. <i>Veterinary Journal</i> , 2011, 190, 305-306.	0.6	1
378	Off-Label Recombinant Factor VIIa Use and Thrombosis in Children: A Multi-Center Cohort Study. <i>Journal of Pediatrics</i> , 2011, 158, 820-825.e1.	0.9	62
379	Hemostasis and Platelet Dysfunction in Asphyxiated Neonates. <i>Journal of Pediatrics</i> , 2011, 158, e35-e39.	0.9	43
380	Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. , 2011, 129, 185-194.		29
381	Imaging of blood plasma coagulation at supported lipid membranes. <i>Journal of Colloid and Interface Science</i> , 2011, 364, 582-587.	5.0	3
382	Anticoagulant effect of polyphenols-rich extracts from black chokeberry and grape seeds. <i>FÄ-toterapÄ-Äç</i> , 2011, 82, 811-817.	1.1	68
386	Unanswered questions in the use of blood component therapy in trauma. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2011, 19, 5.	1.1	18
387	Sex Differences in Antiplatelet Response in Ischemic Stroke. <i>Women's Health</i> , 2011, 7, 465-474.	0.7	12
388	A Reversible Aptamer Improves Outcome and Safety in Murine Models of Stroke and Hemorrhage. <i>Oligonucleotides</i> , 2011, 21, 11-19.	2.7	9
389	Resuscitation and coagulation in the severely injured trauma patient. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011, 366, 192-203.	1.8	49

#	ARTICLE	IF	CITATIONS
390	Massive Transfusion. Journal of the Royal Army Medical Corps, 2011, 157, S277-S283.	0.8	32
391	Review of Continuing Education Course on Hemostasis. Toxicologic Pathology, 2011, 39, 281-288.	0.9	8
392	Review of Current Practice of Blood and Component Transfusion: Critical Issues for the Critically Ill Patient. Journal of the Intensive Care Society, 2011, 12, 134-139.	1.1	0
393	Age, gender and disease-related platelet and neutrophil activation ex vivo in whole blood samples from patients with Behcet's disease. Rheumatology, 2011, 50, 1849-1859.	0.9	38
394	Blood Utilization in Neonates and Infants Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass. World Journal for Pediatric & Congenital Heart Surgery, 2011, 2, 382-392.	0.3	5
395	Modulation of Prothrombinase Assembly and Activity by Phosphatidylethanolamine. Journal of Biological Chemistry, 2011, 286, 35535-35542.	1.6	20
396	Continuing Education Course #2: Current Understanding of Hemostasis. Toxicologic Pathology, 2011, 39, 273-280.	0.9	254
397	Recombinant factor VIIa in post-partum hemorrhage: A new weapon in obstetrician's armamentarium. North American Journal of Medical Sciences, 2012, 4, 157.	1.7	7
398	Coagulation management. Current Opinion in Critical Care, 2012, 18, 641-646.	1.6	12
399	Prohemostatic Treatment in Cardiac Surgery. Seminars in Thrombosis and Hemostasis, 2012, 38, 237-243.	1.5	16
400	The effects of proton radiation on the prothrombin and partial thromboplastin times of irradiated ferrets. International Journal of Radiation Biology, 2012, 88, 327-334.	1.0	23
401	Anticoagulation protocols for minimized cardiopulmonary bypass. , 2012, , 17-34.		0
402	Reduction of Fresh Frozen Plasma Requirements by Perioperative Point-of-Care Coagulation Management with Early Calculated Goal-Directed Therapy. Transfusion Medicine and Hemotherapy, 2012, 39, 104-113.	0.7	193
403	Admission Rapid Thrombelastography Can Replace Conventional Coagulation Tests in the Emergency Department. Annals of Surgery, 2012, 256, 476-486.	2.1	340
404	Review of the Fibrinolytic System: Comparison of Different Antifibrinolytics used During Cardiopulmonary Bypass. Recent Patents on Cardiovascular Drug Discovery, 2012, 7, 175-179.	1.5	10
405	Management of Gynecologic Surgery in the Patient With Factor XI Deficiency. Obstetrical and Gynecological Survey, 2012, 67, 291-297.	0.2	3
406	Different recovery profiles of coagulation factors, thrombin generation, and coagulation function after hemorrhagic shock in pigs. Journal of Trauma, 2012, 73, 640-647.	2.3	13
407	Nuevos anticoagulantes: ¿cuántos de nuestros pacientes anticoagulados pueden tomarlos?. Revista Clínica De Medicina De Familia, 2012, 5, 151-157.	0.1	0

#	ARTICLE	IF	CITATIONS
408	Society of Cardiovascular Anesthesiologists. Anesthesia and Analgesia, 2012, 114, 259.	1.1	0
409	Mechanisms and monitoring of bypassing agent therapy. Journal of Thrombosis and Haemostasis, 2012, 10, 1478-1485.	1.9	91
410	Fibrinogen and Hemostasis. Anesthesia and Analgesia, 2012, 114, 261-274.	1.1	265
411	A new approach to the pathomechanism of amniotic fluid embolism: unknown role of amniotic cells in the induction of disseminated intravascular coagulation. Asian Pacific Journal of Reproduction, 2012, 1, 326-329.	0.2	3
412	Hemostatic properties of the FVIIa analog NN1731. Thrombosis Research, 2012, 129, S49-S50.	0.8	0
413	Hemodilution is Not Critical in the Pathogenesis of the Acute Coagulopathy of Trauma. Journal of Surgical Research, 2012, 173, 26-30.	0.8	25
414	Inherited bleeding disorders in older women. Maturitas, 2012, 72, 35-41.	1.0	9
416	Oral factor Xa inhibitors for the long-term management of ACS. Nature Reviews Cardiology, 2012, 9, 392-401.	6.1	5
417	Blood coagulation: A puzzle for biologists, a maze for mathematicians. Modeling, Simulation and Applications, 2012, , 41-75.	1.3	5
418	Platelet Function in Health and Disease: from Molecular Mechanisms, Redox Considerations to Novel Therapeutic Opportunities. Antioxidants and Redox Signaling, 2012, 17, 1447-1485.	2.5	57
419	Antithrombotic Strategies to Reduce Adverse Clinical Outcomes in Patients With Acute Coronary Syndrome. American Journal of Cardiology, 2012, 110, 1200-1206.	0.7	5
420	Sistema hemostático: fisiopatología y aproximación clínica y diagnóstica. Medicine, 2012, 11, 1327-1336.	0.0	0
421	Low Concentration Detergent Sclerosants Induce Platelet Activation but Inhibit Aggregation due to Suppression of GPIIb/IIIa Activation in vitro. Thrombosis Research, 2012, 130, 472-478.	0.8	21
423	Evaluation of Hemostasis. , 2012, , 191-233.		6
424	Use of Activated Recombinant Factor VII in Severe Bleeding – Evidence for Efficacy and Safety in Trauma, Postpartum Hemorrhage, Cardiac Surgery, and Gastrointestinal Bleeding. Transfusion Medicine and Hemotherapy, 2012, 39, 139-150.	0.7	21
425	Management of Severe Traumatic Brain Injury. , 2012, , .		5
426	Hemostasis, Surgical Bleeding, and Transfusion. , 2012, , 35-47.		9
428	Modeling of Physiological Flows. Modeling, Simulation and Applications, 2012, , .	1.3	18

#	ARTICLE	IF	CITATIONS
429	Factor V Leiden and Inflammation. <i>Thrombosis</i> , 2012, 2012, 1-10.	1.4	14
430	Contraindications - Hemorrhage and Coagulopathy, and Patient Refusal. , 0, , .		0
431	Reduced coagulation at high altitude identified by thromboelastography. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1066-1071.	1.8	30
432	Coagulation Abnormalities in Acute Pancreatitis. , 0, , .		2
433	Haemostasis and thrombosis. , 0, , 71-91.		0
434	A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies. <i>Thrombosis and Haemostasis</i> , 2012, 107, 288-301.	1.8	40
438	Initial experiences with point-of-care rapid thrombelastography for management of life-threatening postinjury coagulopathy. <i>Transfusion</i> , 2012, 52, 23-33.	0.8	111
439	Platelet signaling—A primer. <i>Journal of Veterinary Emergency and Critical Care</i> , 2012, 22, 5-29.	0.4	28
440	Diagnosis and treatment of platelet hyperactivity in relation to thrombosis in dogs and cats. <i>Journal of Veterinary Emergency and Critical Care</i> , 2012, 22, 42-58.	0.4	10
441	Early Platelet Dysfunction: An Unrecognized Role in the Acute Coagulopathy of Trauma. <i>Journal of the American College of Surgeons</i> , 2012, 214, 739-746.	0.2	269
442	Thrombin receptor levels in platelet concentrates during storage and their impact on platelet functionality. <i>Transfusion</i> , 2012, 52, 1253-1259.	0.8	18
443	A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 870-880.	1.9	57
444	Early and individualized goal-directed therapy for trauma-induced coagulopathy. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2012, 20, 15.	1.1	187
446	Clinical practice. <i>European Journal of Pediatrics</i> , 2012, 171, 207-214.	1.3	21
447	Historic View of Hemorrhage Management. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2013, 27, S3-S5.	0.6	0
448	Thrombin inhibition by the serpins. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 254-264.	1.9	60
452	Hemophilias and Other Disorders of Hemostasis. , 2013, , 1-33.		12
453	Thromboprophylaxis for trauma patients. <i>The Cochrane Library</i> , 2013, , CD008303.	1.5	80

#	ARTICLE	IF	CITATIONS
454	Mortality in virulent canine babesiosis is associated with a consumptive coagulopathy. <i>Veterinary Journal</i> , 2013, 196, 213-217.	0.6	29
455	Investigational anticoagulants for hematological conditions: a new generation of therapies. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1281-1294.	1.9	8
456	Neonatal hematology. <i>Seminars in Pediatric Surgery</i> , 2013, 22, 199-204.	0.5	87
457	Haemostasis. <i>Medicine</i> , 2013, 41, 208-211.	0.2	7
458	The skin and hypercoagulable states. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 450-462.	0.6	63
459	Changes in fibrinogen availability and utilization in an animal model of traumatic coagulopathy. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2013, 21, 56.	1.1	14
460	Management of bleeding and coagulopathy following major trauma: an updated European guideline. <i>Critical Care</i> , 2013, 17, R76.	2.5	780
461	Current Diagnostic Trends in Coagulation Disorders Among Dogs and Cats. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2013, 43, 1349-1372.	0.5	29
463	Hemostatic Abnormalities in Uncomplicated Babesiosis (<i>Babesia rossi</i>) in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2013, 27, 150-156.	0.6	17
464	Acute normovolaemic haemodilution in cirrhotic patients undergoing major liver resection: Role of ROTEM. <i>Egyptian Journal of Anaesthesia</i> , 2013, 29, 53-60.	0.2	1
465	Clinically relevant concepts of haemostasis and detection of coagulopathy after trauma and surgery. <i>Revista Espa�ola De Anestesiolog�a Y Reanimaci�n</i> , 2013, 60, 485-488.	0.1	0
466	Clinical aspects of coagulation and haemorrhage. <i>Anaesthesia and Intensive Care Medicine</i> , 2013, 14, 57-62.	0.1	1
467	Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: Comparison with acute coagulopathy of trauma-shock. <i>Surgery</i> , 2013, 154, 48-57.	1.0	54
468	Interactions Between Platelets and the Coagulation System. , 2013, , 425-451.		12
469	Prothrombotic mechanisms and anticoagulant therapy in dogs with immune-mediated hemolytic anemia. <i>Journal of Veterinary Emergency and Critical Care</i> , 2013, 23, 3-13.	0.4	46
470	Cell-ECM Interactions in Repair and Regeneration. , 2013, , 191-226.		1
471	Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 826-835.	1.9	110
472	Thromboelastometry guided therapy of severe bleeding. <i>Hamostaseologie</i> , 2013, 33, 51-61.	0.9	101

#	ARTICLE	IF	CITATIONS
473	A novel coagulation assay incorporating adherent endothelial cells in thromboelastometry. <i>Thrombosis and Haemostasis</i> , 2013, 109, 869-877.	1.8	27
474	General mechanisms of coagulation and targets of anticoagulants (Section I). <i>Thrombosis and Haemostasis</i> , 2013, 109, 569-579.	1.8	165
475	Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. <i>Thrombosis and Haemostasis</i> , 2013, 110, 162-172.	1.8	131
476	<i>Thrombosis</i> . , 2013, , 67-77.		1
477	Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease. <i>Circulation</i> , 2013, 128, 2622-2703.	1.6	260
478	Role of Fibrinolysis in Sepsis. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 392-399.	1.5	81
479	Comparison between human and porcine thromboelastograph parameters in response to ex-vivo changes to platelets, plasma, and red blood cells. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 818-829.	0.5	31
480	Ex-vivo response to blood products and haemostatic agents after paediatric cardiac surgery. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 587-592.	0.5	11
481	Clinical utility of viscoelastic tests of coagulation in patients with liver disease. <i>Liver International</i> , 2013, 33, 961-974.	1.9	84
482	A perioperative uncontrollable bleeding in an elderly patient with acquired hemophilia A: a case report. <i>Clinical Case Reports (discontinued)</i> , 2013, 1, 3-6.	0.2	4
483	Monitoring <sc>rFVIII</sc> prophylaxis dosing using global haemostasis assays. <i>Haemophilia</i> , 2013, 19, 409-414.	1.0	31
484	Practical coagulation for the blood banker. <i>Transfusion</i> , 2013, 53, 1594-1602.	0.8	20
485	- Immunobiotics and Allergy. , 2013, , 226-258.		1
486	FUNCTIONAL FIBRINOGEN ASSAY INDICATES THAT FIBRINOGEN IS CRITICAL IN CORRECTING ABNORMAL CLOT STRENGTH FOLLOWING TRAUMA. <i>Shock</i> , 2013, 39, 45-49.	1.0	155
487	Platelets are dominant contributors to hypercoagulability after injury. <i>Journal of Trauma and Acute Care Surgery</i> , 2013, 74, 756-765.	1.1	85
488	Practical application of point-of-care coagulation testing to guide treatment decisions in trauma. <i>Journal of Trauma and Acute Care Surgery</i> , 2013, 74, 1587-1598.	1.1	91
489	Coagulopathies in Orthopaedics. <i>Journal of Orthopaedic Trauma</i> , 2013, 27, 236-241.	0.7	22
490	<i>Blood and Coagulation</i> . , 2013, , 615-627.		0

#	ARTICLE	IF	CITATIONS
491	Tutorial in Oral antithrombotic therapy: Biology and dental implications. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2013, 18, e461-e472.	0.7	25
492	Disorders of Coagulation in the Neonate. , 2014, , 1586-1594.		0
493	Illustrated operative management of spontaneous bleeding and compartment syndrome of the lower extremity in a patient with acquired hemophilia A: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 132.	0.4	9
494	Fibrinogen and factor XIII at the intersection of coagulation, fibrinolysis and inflammation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 649-658.	1.8	75
495	The coagulation system and its function in early immune defense. <i>Thrombosis and Haemostasis</i> , 2014, 112, 640-648.	1.8	92
496	Clot waveform analysis in patients with haemophilia A. <i>Hamostaseologie</i> , 2014, 34, S48-S62.	0.9	21
498	Molecular mechanisms of thrombosis. Fundamental and applied aspects of the contact activation. <i>Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology</i> , 2014, 8, 279-289.	0.3	1
499	Effect of thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review. <i>Critical Care</i> , 2014, 18, 518.	2.5	258
500	Platelet dysfunction in injured patients. <i>Molecular and Cellular Therapies</i> , 2014, 2, 37.	0.2	15
501	Hemophilias and Other Disorders of Hemostasis. , 2014, , .		2
502	Ca ²⁺ switches the effect of PS-containing membranes on Factor Xa from activating to inhibiting: implications for initiation of blood coagulation. <i>Biochemical Journal</i> , 2014, 462, 591-601.	1.7	18
503	Preoperative assessment of coagulation and bleeding risk. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2014, 75, C71-C74.	0.2	0
504	Reversing targeted oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 518-523.	0.9	4
505	Hematologic variables and venous thrombosis: red cell distribution width and blood monocyte count are associated with an increased risk. <i>Haematologica</i> , 2014, 99, 194-200.	1.7	83
506	Trauma-Induced Coagulopathy: An Institution's 35 Year Perspective on Practice and Research. <i>Scandinavian Journal of Surgery</i> , 2014, 103, 89-103.	1.3	80
507	What is happening? The evolving role of the blood bank in the management of the bleeding patient: The impact of TEG as an early diagnostic predictor for bleeding. <i>Transfusion and Apheresis Science</i> , 2014, 51, 105-110.	0.5	13
508	Role of Oral Factor Xa Inhibitors after Acute Coronary Syndrome. <i>Cardiology</i> , 2014, 129, 224-232.	0.6	8
509	Intra- and inter-centre standardisation of thromboelastography (TEG®). <i>Anaesthesia</i> , 2014, 69, 883-890.	1.8	40

#	ARTICLE	IF	CITATIONS
510	Effects of hematocrit and red blood cell-independent viscosity on canine thromboelastographic tracings. <i>Transfusion</i> , 2014, 54, 727-734.	0.8	48
511	Postinjury Hyperfibrinogenemia Compromises Efficacy of Heparin-Based Venous Thromboembolism Prophylaxis. <i>Shock</i> , 2014, 41, 33-39.	1.0	39
512	Utility of Thromboelastography in Traumatic Brain Injury and the Neuroscience Intensive Care Unit. <i>Journal of Neuroscience Nursing</i> , 2014, 46, 66-70.	0.7	6
513	Promising coagulation factor VIII bypassing strategies for patients with haemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 539-552.	0.5	2
514	Characterization of the hypercoagulable state following severe orthopedic trauma. <i>Journal of Trauma and Acute Care Surgery</i> , 2014, 77, 231-237.	1.1	19
516	Trauma-Induced Coagulopathy. <i>Critical Care Nurse</i> , 2014, 34, 54-63.	0.5	14
517	Strategies for the management of haemorrhage following pelvic fractures and associated trauma-induced coagulopathy. <i>Bone and Joint Journal</i> , 2014, 96-B, 1143-1154.	1.9	51
518	Molecular Basis of Thrombophilia / MOLEKULARNE OSNOVE TROMBOFILIJE. <i>Journal of Medical Biochemistry</i> , 2014, 33, 22-27.	0.7	7
519	Partnership on Rotational ViscoElastic Test Standardization (PROVETS): Evidence-based guidelines on rotational viscoelastic assays in veterinary medicine. <i>Journal of Veterinary Emergency and Critical Care</i> , 2014, 24, 1-22.	0.4	86
521	Emerging paradigms in arterial thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 4-11.	1.0	6
525	First Molecular Analysis of <i>F8</i> Gene in Algeria. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 741-748.	0.7	2
526	Polyphenol compounds belonging to flavonoids inhibit activity of coagulation factor X. <i>International Journal of Biological Macromolecules</i> , 2014, 65, 129-135.	3.6	49
527	Clinical models and biochemical predictors of VTE in lung cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 771-789.	2.7	13
528	Monitoring Technologies in Acute Care Environments. , 2014, , .		12
529	Implementation of an off-label recombinant factor VIIa protocol for patients with critical bleeding at an academic medical center. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 447-452.	1.0	11
530	Inflammation-induced haemostatic response in layer chickens infected with <i>Streptococcus equi</i> subsp. <i>zooepidemicus</i> as evaluated by fibrinogen, prothrombin time and thromboelastography. <i>Avian Pathology</i> , 2014, 43, 364-370.	0.8	5
531	Challenges and Priorities for Research. <i>Circulation</i> , 2014, 130, 1192-1203.	1.6	28
532	Adverse Outcome Pathway and Risks of Anticoagulant Rodenticides to Predatory Wildlife. <i>Environmental Science & Technology</i> , 2014, 48, 8433-8445.	4.6	154

#	ARTICLE	IF	CITATIONS
533	Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 2065-2069.	1.9	9
534	The systemic immune response to trauma: an overview of pathophysiology and treatment. <i>Lancet</i> , The, 2014, 384, 1455-1465.	6.3	607
535	Fibrinogen concentrate for bleeding – a systematic review. <i>Acta Anaesthesiologica Scandinavica</i> , 2014, 58, 1061-1074.	0.7	53
536	Measurement of Dabigatran in Standardly Used Clinical Assays, Whole Blood Viscoelastic Coagulation, and Thrombin Generation Assays. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 479-501.	0.7	29
537	Trauma-Induced Coagulopathy. <i>Current Anesthesiology Reports</i> , 2014, 4, 189-199.	0.9	57
538	An overview of mathematical modeling of thrombus formation under flow. <i>Thrombosis Research</i> , 2014, 133, S12-S14.	0.8	47
539	Abnormal blood clot formation induced by temperature responsive polymers by altered fibrin polymerization and platelet binding. <i>Biomaterials</i> , 2014, 35, 2518-2528.	5.7	21
540	Biological effects of space radiation and development of effective countermeasures. <i>Life Sciences in Space Research</i> , 2014, 1, 10-43.	1.2	136
541	Natural inhibitors of thrombin. <i>Thrombosis and Haemostasis</i> , 2014, 111, 583-589.	1.8	47
542	Tissue Factor Noncoagulant Signaling: Mechanisms and Implications for Cell Migration and Apoptosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 691-699.	1.5	24
543	Early hemostatic responses to trauma identified with hierarchical clustering analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 978-988.	1.9	35
544	A clinician's guide to viscoelastic testing in the perioperative period. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2015, 76, 690-695.	0.2	1
545	Sonic Estimation of Elasticity via Resonance (SEER). , 2015, , .		0
546	Thromboelastography on plasma reveals delayed clot formation and accelerated clot lyses in HIV-1 infected persons compared with healthy controls. <i>BMC Infectious Diseases</i> , 2015, 15, 388.	1.3	5
547	Viscoelastic measurements of platelet function, not fibrinogen function, predicts sensitivity to tissue-type plasminogen activator in trauma patients. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1878-1887.	1.9	85
548	Effect of Compression Devices on Preventing Deep Vein Thrombosis Among Adult Trauma Patients. <i>Dimensions of Critical Care Nursing</i> , 2015, 34, 289-300.	0.4	12
549	Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1279-1284.	1.9	48
550	Postinjury fibrinolysis shutdown. <i>Journal of Trauma and Acute Care Surgery</i> , 2015, 78, S65-S69.	1.1	76

#	ARTICLE	IF	CITATIONS
551	Platelet function in reconstituted whole blood variants. <i>Journal of Trauma and Acute Care Surgery</i> , 2015, 79, 797-804.	1.1	14
552	Developmental hemostasis II. , 0, , 119-132.		0
553	Bioassay-Guided Fractionation of <i>Melastoma malabathricum</i> Linn. Leaf Solid Phase Extraction Fraction and Its Anticoagulant Activity. <i>Molecules</i> , 2015, 20, 3697-3715.	1.7	9
555	The Cell-Based Coagulation Model. , 2015, , 3-11.		7
556	A refined model of the genomic basis for phenotypic variation in vertebrate hemostasis. <i>BMC Evolutionary Biology</i> , 2015, 15, 124.	3.2	16
557	Thromboelastographic Study of Psychophysiological Stress. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 497-512.	0.7	7
558	Altered Flow Changes Thrombin Generation Rate of Circulating Platelets. <i>Annals of Biomedical Engineering</i> , 2015, 43, 2827-2837.	1.3	5
559	Thromboelastography in Selected Avian Species. <i>Journal of Avian Medicine and Surgery</i> , 2015, 29, 282-289.	0.6	17
560	Preoperative Thromboelastometry as a Predictor of Transfusion Requirements during Adult Living Donor Liver Transplantation. <i>Transfusion Medicine and Hemotherapy</i> , 2015, 42, 99-108.	0.7	51
561	Neonatal haemostasis and the management of neonatal thrombosis. <i>British Journal of Haematology</i> , 2015, 169, 324-332.	1.2	38
562	Management of traumatic haemorrhage – the European perspective. <i>Anaesthesia</i> , 2015, 70, 102.	1.8	44
563	Point-of-care monitoring of haemostasis. <i>Anaesthesia</i> , 2015, 70, 73.	1.8	45
564	Shock releases bile acid-inducing platelet inhibition and fibrinolysis. <i>Journal of Surgical Research</i> , 2015, 195, 390-395.	0.8	36
565	Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. <i>Critical Care</i> , 2015, 19, 72.	2.5	100
566	Procoagulant Platelets and the Pathways Leading to Cell Death. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 405-412.	1.5	20
567	Hemostasis and Thrombosis in Trauma Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 026-034.	1.5	24
568	Safety update on the use of recombinant activated factor VII in approved indications. <i>Blood Reviews</i> , 2015, 29, S34-S41.	2.8	50
569	Conserved <i>Amblyomma americanum</i> tick Serpin19, an inhibitor of blood clotting factors Xa and XIa, trypsin and plasmin, has anti-haemostatic functions. <i>International Journal for Parasitology</i> , 2015, 45, 613-627.	1.3	48

#	ARTICLE	IF	CITATIONS
570	Point-of-care haemostasis monitoring during liver transplantation reduces transfusion requirements and improves patient outcome. <i>Clinica Chimica Acta</i> , 2015, 446, 277-283.	0.5	60
571	Endothelial cell dysfunction in viral hemorrhage and edema. <i>Frontiers in Microbiology</i> , 2014, 5, 733.	1.5	38
572	Colon Polyps and the Prevention of Colorectal Cancer. , 2015, , .		3
573	Factor Xa dimerization competes with prothrombinase complex formation on platelet-like membrane surfaces. <i>Biochemical Journal</i> , 2015, 467, 37-46.	1.7	5
574	Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion. <i>Inflammation</i> , 2015, 38, 1707-1726.	1.7	21
575	Detection of acute traumatic coagulopathy and massive transfusion requirements by means of rotational thromboelastometry: an international prospective validation study. <i>Critical Care</i> , 2015, 19, 97.	2.5	137
576	Thresholds for Perioperative Administration of Hemostatic Blood Components and Coagulation Factor Concentrates: An Unmet Medical Need. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, 768-776.	0.6	18
577	Evaluation of fibrinogen concentrates and prothrombin complex concentrates on coagulation changes in a hypothermic in vitro model using thromboelastometry and thromboelastography. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 407-414.	0.6	6
578	The coagulopathy of acute sepsis. <i>Current Opinion in Anaesthesiology</i> , 2015, 28, 227-236.	0.9	208
579	Tranexamic acid. <i>Current Opinion in Anaesthesiology</i> , 2015, 28, 191-200.	0.9	28
580	Bleeding Disorders. , 2015, , 554-567.		5
581	Coagulation in Liver Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 447-454.	1.5	27
582	Clinical Utility of Viscoelastic Tests of Coagulation (TEG/ROTEM) in Patients with Liver Disease and during Liver Transplantation. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 527-537.	1.5	130
583	Evaluation of dynamic parameters of thrombus formation measured on whole blood using rotational thromboelastometry in children undergoing cardiac surgery: a descriptive study. <i>Paediatric Anaesthesia</i> , 2015, 25, 573-579.	0.6	15
584	Hemostasis and thrombosis beyond biochemistry: roles of geometry, flow and diffusion. <i>Thrombosis Research</i> , 2015, 136, 699-711.	0.8	51
585	Biomimetic biosensor to distinguish between inhibitory and non-inhibitory factor VIII antibodies. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 5685-5693.	1.9	2
587	mRNA expression of genes involved in inflammation and haemostasis in equine fibroblast-like synoviocytes following exposure to lipopolysaccharide, fibrinogen and thrombin. <i>BMC Veterinary Research</i> , 2015, 11, 141.	0.7	11
588	Thromboelastography Values in Hispaniolan Amazon Parrots (<i>Amazona ventralis</i>): A Pilot Study. <i>Journal of Avian Medicine and Surgery</i> , 2015, 29, 174-180.	0.6	12

#	ARTICLE	IF	CITATIONS
589	Dosing of rivaroxaban by indication: getting the right dose for the patient. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1665-1677.	1.5	3
591	The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen). Integrative Biology (United Tj ETQq1 1 0.784314 rgBT /3/overlock	1.4	13
592	Fluid Mechanics of Blood Clot Formation. Annual Review of Fluid Mechanics, 2015, 47, 377-403.	10.8	226
593	Perioperative Hemostasis. , 2015, , .		4
594	Viscoelastic hemostatic fibrinogen assays detect fibrinolysis early. European Journal of Trauma and Emergency Surgery, 2015, 41, 49-56.	0.8	52
595	Coagulopathy and transfusion therapy in pediatric liver transplantation. World Journal of Gastroenterology, 2016, 22, 2005.	1.4	33
596	Platelets miRNA as a Prediction Marker of Thrombotic Episodes. Disease Markers, 2016, 2016, 1-7.	0.6	29
597	Evaluation of Potential Clinical Surrogate Markers of a Trauma Induced Alteration of Clotting Factor Activities. BioMed Research International, 2016, 2016, 1-10.	0.9	3
598	Disorders of Coagulation. , 2016, , 279-333.		2
599	Novel Dielectric Coagulometer Identifies Hypercoagulability in Patients with a High CHADS2 Score without Atrial Fibrillation. PLoS ONE, 2016, 11, e0156557.	1.1	7
600	A comparative study of tissue factor and kaolin on blood coagulation assays using rotational thromboelastometry and thromboelastography. Blood Coagulation and Fibrinolysis, 2016, 27, 31-41.	0.5	17
601	Coagulation management in trauma-associated coagulopathy. Current Opinion in Anaesthesiology, 2016, 29, 245-249.	0.9	13
602	Assessment of hemostatic changes in a model of acute hemorrhage in dogs. Journal of Veterinary Emergency and Critical Care, 2016, 26, 333-343.	0.4	17
603	Overview of Blood Coagulation and the Pathophysiology of Blood Coagulation Disorders. , 2016, , 714-722.		9
604	Life-threatening hemorrhage from acquired hemophilia A as a presenting manifestation of prostate cancer. Journal of Community Hospital Internal Medicine Perspectives, 2016, 6, 32461.	0.4	7
605	Coagulation complications following trauma. Military Medical Research, 2016, 3, 35.	1.9	25
606	Acute traumatic coagulopathy: pathophysiology and resuscitation. British Journal of Anaesthesia, 2016, 117, iii31-iii43.	1.5	117
607	Targeted Coagulation Management in Severe Trauma: The Controversies and the Evidence. Anesthesia and Analgesia, 2016, 123, 910-924.	1.1	49

#	ARTICLE	IF	CITATIONS
608	Alteraciones del sistema hemostático. Estrategias diagnósticas de la patología hemorrágica. Coagulopatías congénitas. <i>Medicine</i> , 2016, 12, 1255-1266.	0.0	0
609	Point of Care Assessment of Coagulation. <i>Topics in Companion Animal Medicine</i> , 2016, 31, 11-17.	0.4	13
610	Deep venous thrombosis: The valve cusp hypoxia thesis and its incompatibility with modern orthodoxy. <i>Medical Hypotheses</i> , 2016, 86, 60-66.	0.8	7
611	Platelet Function in Thrombosis and Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 183-184.	1.5	36
612	The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. <i>Critical Care</i> , 2016, 20, 100.	2.5	1,014
614	Why Do Patients Bleed?. <i>The Surgery Journal</i> , 2016, 02, e29-e43.	0.3	16
615	Choice of Fluid Therapy and Bleeding Risk After Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2016, 30, 1094-1103.	0.6	9
616	Platelet function in baboons and humans – A comparative study of whole blood using impedance platelet aggregometry (Multiplate®). <i>Thrombosis Research</i> , 2016, 147, 115-121.	0.8	4
617	Coagulation factors bound to procoagulant platelets concentrate in cap structures to promote clotting. <i>Blood</i> , 2016, 128, 1745-1755.	0.6	90
618	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1413-1447.	1.4	10
619	Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA [®] in prophylactic therapy. <i>Haemophilia</i> , 2016, 22, 615-624.	1.0	27
620	Popular naturally occurring antioxidants as potential anticoagulant drugs. <i>Chemico-Biological Interactions</i> , 2016, 257, 35-45.	1.7	25
621	Structure-activity relationship studies for multitarget antithrombotic drugs. <i>Future Medicinal Chemistry</i> , 2016, 8, 2305-2355.	1.1	8
622	Disseminated intravascular coagulation. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16037.	18.1	367
623	Monitoring and Treatment of Coagulation Disorders in End-Stage Liver Disease. <i>Visceral Medicine</i> , 2016, 32, 241-248.	0.5	47
624	Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection. <i>Nature Communications</i> , 2016, 7, 12616.	5.8	61
626	Synergy Between Tissue Factor and Exogenous Factor XIa in Initiating Coagulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2334-2345.	1.1	13
627	Coagulative safety of epidural catheters after major upper gastrointestinal surgery: advanced and routine coagulation analysis in 38 patients. <i>Perioperative Medicine (London, England)</i> , 2016, 5, 28.	0.6	16

#	ARTICLE	IF	CITATIONS
628	Retrospective evaluation of shortened prothrombin time or activated partial thromboplastin time for the diagnosis of hypercoagulability in dogs: 25 cases (2006–2011). <i>Journal of Veterinary Emergency and Critical Care</i> , 2016, 26, 398-405.	0.4	29
629	Moojenactivase, a novel pro-coagulant PIII metalloprotease isolated from <i>Bothrops moojeni</i> snake venom, activates coagulation factors II and X and induces tissue factor up-regulation in leukocytes. <i>Archives of Toxicology</i> , 2016, 90, 1261-1278.	1.9	26
630	Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 1-9.	2.0	32
631	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. <i>Vascular Pharmacology</i> , 2016, 81, 1-14.	1.0	8
632	Sonic Estimation of Elasticity via Resonance: A New Method of Assessing Hemostasis. <i>Annals of Biomedical Engineering</i> , 2016, 44, 1405-1424.	1.3	34
633	Use of Plasma for Acquired Coagulation Factor Deficiencies in Critical Care. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 095-101.	1.5	7
634	Clinical aspects of coagulation and haemorrhage. <i>Anaesthesia and Intensive Care Medicine</i> , 2016, 17, 86-91.	0.1	1
635	Global assays in hemophilia. <i>Seminars in Hematology</i> , 2016, 53, 40-45.	1.8	26
636	Hysteresis-like binding of coagulation factors X/Xa to procoagulant activated platelets and phospholipids results from multistep association and membrane-dependent multimerization. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2016, 1858, 1216-1227.	1.4	21
637	Platelets as Biomarkers of Coronary Artery Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 223-233.	1.5	27
638	Platelets and Antiplatelet Therapy in Patients with Coronary Artery Disease and Diabetes. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 234-241.	1.5	25
639	Pathophysiology of Coagulation. , 2016, , 1-17.		0
640	General Aspects of Platelet Function Tests. , 2016, , 35-58.		0
641	Blood Products, Derivates, and Prohemostatic Drugs. , 2016, , 69-87.		0
642	Untangling the complexity of blood coagulation network: use of computational modelling in pharmacology and diagnostics. <i>Briefings in Bioinformatics</i> , 2016, 17, 429-439.	3.2	23
643	A Review of Hormonal Contraception and Venous Thromboembolism in Adolescents. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2016, 29, 402-408.	0.3	6
644	Anticoagulation strategies and difficulties in neonatal and paediatric extracorporeal membrane oxygenation (ECMO). <i>Perfusion (United Kingdom)</i> , 2016, 31, 95-102.	0.5	25
645	Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 477-486.	1.9	28

#	ARTICLE	IF	CITATIONS
646	Rare bleeding disorders-old diseases in the era of novel options for therapy. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 63-68.	0.6	9
648	Platelet Transfusion in Critical Care and Surgery. <i>Shock</i> , 2017, 47, 537-549.	1.0	34
649	Global hemostasis in healthy bitches during pregnancy and at different estrous cycle stages: Evaluation of routine hemostatic tests and thromboelastometry. <i>Theriogenology</i> , 2017, 97, 57-66.	0.9	14
650	<i>Clinical Pathology.</i> , 2017, , 112-144.		0
651	Platelets and hemophilia: A review of the literature. <i>Thrombosis Research</i> , 2017, 155, 131-139.	0.8	11
652	The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology. <i>Internal and Emergency Medicine</i> , 2017, 12, 981-991.	1.0	23
653	Platelet transfusions reduce fibrinolysis but do not restore platelet function during trauma hemorrhage. <i>Journal of Trauma and Acute Care Surgery</i> , 2017, 83, 388-397.	1.1	56
654	Endothelial Cell-derived Extracellular Vesicles Size-dependently Exert Procoagulant Activity Detected by Thromboelastometry. <i>Scientific Reports</i> , 2017, 7, 3707.	1.6	30
656	Progresses in understanding trauma-induced coagulopathy and the underlying mechanism. <i>Chinese Journal of Traumatology - English Edition</i> , 2017, 20, 133-136.	0.7	17
657	Haemotherapy algorithm for the management of trauma-induced coagulopathy. <i>Current Opinion in Anaesthesiology</i> , 2017, 30, 265-276.	0.9	12
658	Tranexamic Acid Use in Prehospital Uncontrolled Hemorrhage. <i>Wilderness and Environmental Medicine</i> , 2017, 28, S50-S60.	0.4	30
659	Management of neurologic complications of coagulopathies. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2017, 141, 743-764.	1.0	7
660	Association between ascites and primary hyperfibrinolysis: A cohort study in 210 dogs. <i>Veterinary Journal</i> , 2017, 223, 12-20.	0.6	10
661	Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data. <i>Haemophilia</i> , 2017, 23, 50-58.	1.0	21
662	<i>Coagulation Monitoring.</i> , 2017, , 327-354.		0
663	Microvasculature on a chip: study of the Endothelial Surface Layer and the flow structure of Red Blood Cells. <i>Scientific Reports</i> , 2017, 7, 45036.	1.6	66
664	Role of Thromboelastography Platelet Mapping and International Normalized Ratio in Defining Normocoagulability During Anticoagulation for Mechanical Circulatory Support Devices: A Pilot Retrospective Study. <i>ASAIO Journal</i> , 2017, 63, 24-31.	0.9	19
666	Bio-inspired nanomedicine strategies for artificial blood components. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1464.	3.3	53

#	ARTICLE	IF	CITATIONS
667	Haemostasis. <i>Medicine</i> , 2017, 45, 204-208.	0.2	13
668	Fibrinogen in traumatic haemorrhage: A narrative review. <i>Injury</i> , 2017, 48, 230-242.	0.7	37
669	In vitro characterization of SynthoPlate [®] (synthetic platelet) technology and its in vivo evaluation in severely thrombocytopenic mice. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 375-387.	1.9	47
670	Design and characterization of an APC-specific serpin for the treatment of hemophilia. <i>Blood</i> , 2017, 129, 105-113.	0.6	119
671	Flavonolignans inhibit ADP induced blood platelets activation and aggregation in whole blood. <i>International Journal of Biological Macromolecules</i> , 2017, 95, 682-688.	3.6	22
672	Vascular Diseases for the Non-Specialist. , 2017, , .		3
674	Neurosurgical applications of viscoelastic hemostatic assays. <i>Neurosurgical Focus</i> , 2017, 43, E9.	1.0	32
675	Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1812-1818.	1.1	15
676	Assessment of Platelet Function in Whole Blood by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2017, 1646, 349-367.	0.4	3
677	Rapid Source-Control Laparotomy: Is There a Mortality Benefit?. <i>Surgical Infections</i> , 2017, 18, 787-792.	0.7	6
678	Developmental hemostasis and ventricular assist devices: A troubled relationship. <i>Progress in Pediatric Cardiology</i> , 2017, 47, 14-20.	0.2	2
679	Coagulopathy in Children With Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, 603-607.	0.9	18
680	Coagulation monitoring correlation with heparin dose in pediatric extracorporeal life support. <i>Perfusion (United Kingdom)</i> , 2017, 32, 675-685.	0.5	33
682	Evaluation of the efficiency under current use of human fibrinogen concentrate in trauma patients with life-threatening hemorrhagic disorders. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 66-71.	0.5	9
683	Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 540-550.	0.5	4
684	Nonhuman primate model of polytraumatic hemorrhagic shock recapitulates early platelet dysfunction observed following severe injury in humans. <i>Journal of Trauma and Acute Care Surgery</i> , 2017, 82, 461-469.	1.1	15
685	Preoperative thrombelastography maximum amplitude predicts massive transfusion in liver transplantation. <i>Journal of Surgical Research</i> , 2017, 220, 171-175.	0.8	33
686	Platelet Function Tests: Preanalytical Variables, Clinical Utility, Advantages, and Disadvantages. <i>Methods in Molecular Biology</i> , 2017, 1646, 305-320.	0.4	27

#	ARTICLE	IF	CITATIONS
687	Vaginal Birth after Cesarean. , 2017, , 80-85.		0
689	Perineal Trauma after Vaginal Delivery: Third and Fourth Degree Lacerations and Hematomas. , 2017, , 99-104.		0
690	Obstetric Anesthesia. , 2017, , 105-115.		0
691	Intrapartum Fetal Monitoring. , 2017, , 116-125.		0
692	Obstetric Ultrasound for the Generalist Obstetrician. , 2017, , 126-142.		0
695	Abnormal Fetal Growth. , 2017, , 161-168.		0
696	Alloimmunization and Non-immune Hydrops Fetalis. , 2017, , 169-178.		0
697	Fetal Anomalies. , 2017, , 179-187.		0
698	Malpresentation. , 2017, , 188-196.		0
699	Intraamniotic Infection. , 2017, , 197-203.		0
700	Multifetal Pregnancy. , 2017, , 204-212.		0
701	Premature Rupture of Fetal Membranes Preterm and at Term. , 2017, , 213-219.		0
702	Preterm Delivery. , 2017, , 220-228.		0
703	Second Trimester Pregnancy Loss. , 2017, , 229-235.		3
704	Third Trimester Fetal Loss. , 2017, , 236-244.		0
705	Antepartum Hemorrhage. , 2017, , 245-251.		0
706	Postpartum Infection. , 2017, , 262-268.		0
707	The Obstetric Patient with Trauma. , 2017, , 269-278.		0

#	ARTICLE	IF	CITATIONS
708	Post-term Pregnancy. , 2017, , 279-285.		0
709	Musculoskeletal Disorders. , 2017, , 286-295.		0
710	Obesity in Pregnancy. , 2017, , 296-307.		0
712	Cardiovascular Disease in Pregnancy. , 2017, , 324-331.		0
713	Pulmonary Disease in Pregnancy. , 2017, , 332-343.		0
714	Neurological Disease Complicating Pregnancy. , 2017, , 344-354.		0
715	Renal Diseases in Pregnancy. , 2017, , 355-365.		0
716	Hematologic Diseases Complicating Pregnancy. , 2017, , 366-374.		0
717	Gastrointestinal Disorders in Pregnancy. , 2017, , 375-386.		0
718	Selected Endocrine Disorders in Pregnancy. , 2017, , 387-398.		0
719	Diabetes Mellitus in Pregnancy. , 2017, , 399-410.		0
720	Connective Tissue Disorders and Pregnancy. , 2017, , 411-423.		0
721	Dermatologic Disorders and Pregnancy. , 2017, , 424-431.		0
722	Selected Infectious Diseases. , 2017, , 432-441.		0
723	Human Immunodeficiency Virus Infection and Pregnancy. , 2017, , 442-453.		0
724	Psychiatric Diseases in Pregnancy and the Postpartum Period. , 2017, , 454-464.		0
725	Substance Use in Women and Pregnancy. , 2017, , 465-478.		0
726	Cancer in Pregnancy. , 2017, , 479-484.		0

#	ARTICLE	IF	CITATIONS
727	Thromboembolic Complications of Pregnancy. , 2017, , 485-490.		0
728	Disability in Pregnancy. , 2017, , 491-497.		0
729	The History of Obstetrics. , 2017, , 498-510.		0
730	Abnormal Labor. , 2017, , 13-22.		0
732	Factor VII deficiency: a novel missense variant and genotypeâ€phenotype correlation in patients from Southern Italy. Human Genome Variation, 2017, 4, 17048.	0.4	6
733	Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum. , 2017, , 308-314.		0
734	The mechanisms and kinetics of initiation of blood coagulation by the extrinsic tenase complex. Biophysics (Russian Federation), 2017, 62, 291-300.	0.2	6
735	Fibrinogen Early In Severe Trauma study (FEISTY): study protocol for a randomised controlled trial. Trials, 2017, 18, 241.	0.7	56
736	Silk fibroin based carrier system for delivery of fibrinogen and thrombin as coagulant supplements. Journal of Biomedical Materials Research - Part A, 2017, 105, 687-696.	2.1	16
737	Functional improvement of hemostatic dressing by addition of recombinant batroxobin. Acta Biomaterialia, 2017, 48, 175-185.	4.1	53
738	A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity. International Journal of Hematology, 2017, 105, 174-183.	0.7	36
739	Review: The mechanism of blood coagulation, its disorders and measurement in poultry. Livestock Science, 2017, 195, 1-8.	0.6	10
740	Imaging analyses of coagulation-dependent initiation of fibrinolysis on activated platelets and its modification by thrombin-activatable fibrinolysis inhibitor. Thrombosis and Haemostasis, 2017, 117, 682-690.	1.8	13
741	Pathology of Toxicologists. , 2017, , .		0
742	1. Grundlagen der Blutgerinnung. , 2017, , 3-14.		0
744	Genotype and phenotype correlation in intracranial hemorrhage in neonatal factor VII deficiency among Thai children. The Application of Clinical Genetics, 2017, Volume 10, 37-41.	1.4	11
745	Anticoagulation in cirrhosis: a new paradigm?. Clinical and Molecular Hepatology, 2017, 23, 13-21.	4.5	57
746	A new era of thromboelastometry. Einstein (Sao Paulo, Brazil), 2017, 15, 380-385.	0.3	39

#	ARTICLE	IF	CITATIONS
747	Context-dependent risks and benefits of transfusion in the critically ill. <i>International Journal of Clinical Transfusion Medicine</i> , 2017, Volume 5, 29-37.	0.8	0
748	Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation. <i>PLoS ONE</i> , 2017, 12, e0171486.	1.1	16
749	The Complex Process of Haemostasis and Interactions due to Hyperosmotic Fluids. <i>Turkish Journal of Anaesthesiology and Reanimation</i> , 2017, 45, 83-84.	0.8	0
750	Nuevos anticoagulantes orales: actualizaci3n. <i>Revista Chilena De CardiologAa</i> , 2017, 36, 254-263.	0.0	3
751	Applying the Cell-Based Coagulation Model in the Management of Critical Bleeding. <i>Anaesthesia and Intensive Care</i> , 2017, 45, 166-176.	0.2	22
752	Recombinant batroxobin-coated nonwoven chitosan as hemostatic dressing for initial hemorrhage control. <i>International Journal of Biological Macromolecules</i> , 2018, 113, 757-763.	3.6	17
753	Multicenter in vitro thromboelastography and thromboelastometry standardization. <i>Journal of Veterinary Emergency and Critical Care</i> , 2018, 28, 201-212.	0.4	19
754	Factor (F) VIII/VIIa enhances global haemostatic function in the co-presence of bypassing agents and FVIII among patients with haemophilia A with inhibitor. <i>British Journal of Haematology</i> , 2018, 181, 528-536.	1.2	4
755	Foreword: The Prevention and Management of Thrombosis in Obstetrics and Gynecology. <i>Clinical Obstetrics and Gynecology</i> , 2018, 61, 203-205.	0.6	1
756	Intravenous synthetic platelet (SynthoPlate) nanoconstructs reduce bleeding and improve "golden hour"™ survival in a porcine model of traumatic arterial hemorrhage. <i>Scientific Reports</i> , 2018, 8, 3118.	1.6	60
757	Normal reference intervals and the effects of sample handling on dynamic viscoelastic coagulometry (Sonoclot) in healthy adult horses. <i>Journal of Veterinary Emergency and Critical Care</i> , 2018, 28, 39-44.	0.4	4
758	Tissue Factor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 709-725.	1.1	437
759	Misguided by INR in Liver Disease Patients? Implications for Clinicians Including Pain Proceduralists. <i>Anesthesia and Analgesia</i> , 2018, 127, 289-294.	1.1	3
760	Perioperative Coagulation Management in Liver Transplant Recipients. <i>Transplantation</i> , 2018, 102, 578-592.	0.5	68
761	Abnormalities of laboratory coagulation tests versus clinically evident coagulopathic bleeding: results from the prehospital resuscitation on helicopters study (PROHS). <i>Surgery</i> , 2018, 163, 819-826.	1.0	18
762	An increased tendency in fibrinogen activity and its association with a hypo-fibrinolytic state in early stages after injury in patients without acute traumatic coagulopathy (ATC). <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 477-485.	1.0	3
763	THROMBOELASTOGRAPHY IN THE HEALTHY ASIAN ELEPHANT (<i>ELEPHAS MAXIMUS</i>): REFERENCE INTERVALS AND EFFECTS OF STORAGE. <i>Journal of Zoo and Wildlife Medicine</i> , 2018, 49, 54-63.	0.3	9
764	Platelets and Platelet-Inspired Biomaterials Technologies in Wound Healing Applications. <i>ACS Biomaterials Science and Engineering</i> , 2018, 4, 1176-1192.	2.6	55

#	ARTICLE	IF	CITATIONS
765	Von Willebrand Factor: Multimeric Structure and Functional Activity in Patients With Atrial Fibrillation With and Without Oral Anticoagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 647-654.	0.7	7
766	Evaluation of Thromboelastometry in Sepsis in Correlation With Bleeding During Invasive Procedures. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 993-997.	0.7	9
767	Fibrinolysis in trauma: a review. <i>European Journal of Trauma and Emergency Surgery</i> , 2018, 44, 35-44.	0.8	35
768	The influence of inflammation and hematocrit on clot strength in canine thromboelastographic hypercoagulability. <i>Journal of Veterinary Emergency and Critical Care</i> , 2018, 28, 20-30.	0.4	13
769	Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count. <i>European Journal of Haematology</i> , 2018, 100, 286-293.	1.1	10
770	An ex-vivo model of shear-rate-based activation of blood coagulation. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 172-177.	0.5	4
771	Reference ranges of thromboelastography in premature neonates? Still a long way to go. <i>Early Human Development</i> , 2018, 116, 95-96.	0.8	1
772	Viscoelastic Monitoring to Guide Hemostatic Resuscitation in Liver Transplantation Surgery. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2018, 22, 150-163.	0.4	11
773	Anticoagulation in extracorporeal membrane oxygenation. <i>Journal of Emergency and Critical Care Medicine</i> , 2018, 2, 12-12.	0.7	12
774	Coagulation management in liver transplantation: a never-ending story. <i>Minerva Anestesiologica</i> , 2018, 84, 1013-1015.	0.6	3
775	Toward Point-of-Care Assessment of Platelet Count-induced Changes in Whole Blood Coagulation with a Dielectric Microsensor. , 2018, , .		1
776	Procoagulant activity during viral infections. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 1060-1081.	3.0	80
777	Hematological Assessment of a Patient with an Inherited Bleeding Disorder. , 0, , 1-12.		0
778	Effects of anemia and blood transfusion on clot formation and platelet function in patients with septic shock: a substudy of the randomized TRISS trial. <i>Transfusion</i> , 2018, 58, 2807-2818.	0.8	6
779	A novel fibrinogen variant in a Chinese pedigree with congenital dysfibrinogenemia caused by FGA P. Arg38Thr mutation. <i>Medicine (United States)</i> , 2018, 97, e12697.	0.4	4
780	Current Hematological Concepts and Viscoelastic-Based Transfusion Practices During Liver Transplantation. <i>Current Transplantation Reports</i> , 2018, 5, 251-263.	0.9	0
781	Sensitivity and Robustness of Spatially Dependent Thrombin Generation and Fibrin Clot Propagation. <i>Biophysical Journal</i> , 2018, 115, 2461-2473.	0.2	23
782	Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids. <i>Prostaglandins and Other Lipid Mediators</i> , 2018, 139, 10-18.	1.0	72

#	ARTICLE	IF	CITATIONS
783	The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2362-2374.	1.9	50
784	Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX. <i>Blood Research</i> , 2018, 53, 41.	0.5	3
785	Thromboelastometry Identified Alteration of Clot Stabilization and Factor XIII Supplementation Need in a Patient with Decompensated Liver Disease Undergoing Liver Biopsy. <i>Case Reports in Gastrointestinal Medicine</i> , 2018, 2018, 1-4.	0.2	3
786	The intra-assay reproducibility of thromboelastography in very low birth weight infants. <i>Early Human Development</i> , 2018, 127, 48-52.	0.8	13
787	Differential Assessment of Factor Xa Activity and Global Blood Coagulability Utilizing Novel Dielectric Coagulometry. <i>Scientific Reports</i> , 2018, 8, 16129.	1.6	3
788	Acquired and Genetic Thrombotic Risk Factors in the Athlete. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 723-733.	1.5	15
790	Reversal of Systemic Anticoagulants and Antiplatelet Therapeutics. <i>Neurosurgery Clinics of North America</i> , 2018, 29, 537-545.	0.8	11
791	FXa Direct Synthetic Inhibitors. , 0, , .		3
792	Mathematical Models of Thrombus Formation and Fibrinolysis. , 2018, , 67-86.		1
793	A ROTEM method using APTT reagent and tissue factor as the clotting activators may better define bleeding heterogeneity in moderate or severe haemophilia A (part I: Study in plasma samples). <i>Thrombosis Research</i> , 2018, 171, 7-13.	0.8	2
794	Optimizing transfusion strategies in damage control resuscitation: current insights. <i>Journal of Blood Medicine</i> , 2018, Volume 9, 117-133.	0.7	13
795	Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice. <i>Blood Advances</i> , 2018, 2, 3126-3136.	2.5	7
796	Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. <i>Critical Pathways in Cardiology</i> , 2018, 17, 53-68.	0.2	2
797	Factor VII and thromboembolism. <i>Trends in Anaesthesia and Critical Care</i> , 2018, 22, 33-40.	0.4	1
798	A local and global sensitivity analysis of a mathematical model of coagulation and platelet deposition under flow. <i>PLoS ONE</i> , 2018, 13, e0200917.	1.1	45
799	Nanoparticles Can Wrap Epithelial Cell Membranes and Relocate Them Across the Epithelial Cell Layer. <i>Nano Letters</i> , 2018, 18, 5294-5305.	4.5	27
800	Coagulation, Microenvironment and Liver Fibrosis. <i>Cells</i> , 2018, 7, 85.	1.8	44
801	Activated protein C plays no major roles in the inhibition of coagulation or increased fibrinolysis in acute coagulopathy of trauma-shock: a systematic review. <i>Thrombosis Journal</i> , 2018, 16, 13.	0.9	24

#	ARTICLE	IF	CITATIONS
802	The reversal of anticoagulation in clinical practice. <i>Clinical Medicine</i> , 2018, 18, 314-319.	0.8	28
803	Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior. <i>Journal of Nanobiotechnology</i> , 2018, 16, 27.	4.2	27
804	Oscillatory shear stress induces hemostatic imbalance in healthy men. <i>Thrombosis Research</i> , 2018, 170, 119-125.	0.8	16
805	Biology of Coagulation and Coagulopathy in Neurologic Surgery. <i>Neurosurgery Clinics of North America</i> , 2018, 29, 475-483.	0.8	5
806	Rational approach to transfusion in liver transplantation. <i>Minerva Anestesiologica</i> , 2018, 84, 378-388.	0.6	23
807	Experimental hypercoagulable state induced by tissue factor expression in monocyte-derived dendritic cells and its modulation by C1 inhibitor. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 219-226.	1.0	4
808	Hemostatic findings of pleural fluid in dogs and the association between pleural effusions and primary hyperfibrinogenolysis: A cohort study of 99 dogs. <i>PLoS ONE</i> , 2018, 13, e0192371.	1.1	6
809	Advances and innovations in haemophilia treatment. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 493-508.	21.5	81
810	Identification of serpins specific for activated protein C using a lysate-based screening assay. <i>Scientific Reports</i> , 2018, 8, 8793.	1.6	14
811	Thromboelastometry as an Alternative Method for Coagulation Assessment in Pediatric Patients Undergoing Invasive Procedures: A Pilot Study. <i>European Journal of Pediatric Surgery</i> , 2019, 29, 298-301.	0.7	6
812	Medications for Hemostasis. , 2019, , 482-499.e7.		2
813	Histone H4 induces platelet ballooning and microparticle release during trauma hemorrhage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17444-17449.	3.3	73
814	New insights into neonatal coagulation: normal clot formation despite lower intra-clot thrombin levels. <i>Pediatric Research</i> , 2019, 86, 719-724.	1.1	13
815	Massive Pulmonary Hemorrhage During Pulmonary Thromboendarterectomy. , 2019, , 73-109.		0
816	Thromboelastography-guided transfusion in dogs with hypocoagulable disorders: a case series. <i>Acta Veterinaria Scandinavica</i> , 2019, 61, 35.	0.5	5
818	Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis. <i>International Journal of Hematology</i> , 2019, 110, 419-430.	0.7	47
819	Trauma-induced coagulopathy: The past, present, and future: A comment. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1567-1569.	1.9	3
820	Limited factor VII a surface localization requirement of the factor VII induced overall thrombin generation in platelet-rich hemophilia A plasma. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 713-717.	1.0	0

#	ARTICLE	IF	CITATIONS
821	Platelet Contributions to Trauma-Induced Coagulopathy: Updates in Post-injury Platelet Biology, Platelet Transfusions, and Emerging Platelet-Based Hemostatic Agents. <i>Current Trauma Reports</i> , 2019, 5, 202-209.	0.6	1
822	Prospective assessment of fibrinolysis in morbid obesity: tissue plasminogen activator resistance improves after bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2019, 15, 1153-1159.	1.0	14
824	Response to Letter to the Editor submitted by Dr. Wada and Dr. Yamakawa re: Trauma-induced coagulopathy: The past, present, and future. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1574-1576.	1.9	1
825	Viscoelastic Monitoring to Guide the Correction of Perioperative Coagulopathy and Massive Transfusion in Patients with Life-Threatening Hemorrhage. <i>Anesthesiology Clinics</i> , 2019, 37, 51-66.	0.6	10
828	Trauma-Induced Coagulopathy. <i>Hamostaseologie</i> , 2019, 39, 020-027.	0.9	16
829	Hemoperfusion leads to impairment in hemostasis and coagulation process in patients with acute pesticide intoxication. <i>Scientific Reports</i> , 2019, 9, 13325.	1.6	7
830	Thrombogenic Risk Induced by Intravascular Mesenchymal Stem Cell Therapy: Current Status and Future Perspectives. <i>Cells</i> , 2019, 8, 1160.	1.8	78
831	Whole blood thrombin generation is distinct from plasma thrombin generation in healthy volunteers and after severe injury. <i>Surgery</i> , 2019, 166, 1122-1127.	1.0	12
832	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2019, 4, 747.	3.0	198
833	Inflammation and coagulation following minimally invasive extracorporeal circulation technologies. <i>Journal of Thoracic Disease</i> , 2019, 11, S1480-S1488.	0.6	25
834	Trauma-targeted delivery of tranexamic acid improves hemostasis and survival in rat liver hemorrhage model. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1632-1644.	1.9	24
837	Blindspots and limitations in viscoelastic testing in pregnancy. <i>International Journal of Obstetric Anesthesia</i> , 2019, 38, 4-9.	0.2	15
838	Managing coagulopathy following PPH. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2019, 61, 106-120.	1.4	23
839	Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. <i>Molecular Therapy</i> , 2019, 27, 1228-1241.	3.7	52
840	Trauma-induced coagulopathy: The past, present, and future. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 852-862.	1.9	159
841	ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs. <i>Journal of Veterinary Internal Medicine</i> , 2019, 33, 1141-1172.	0.6	71
842	The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. <i>Critical Care</i> , 2019, 23, 98.	2.5	878
843	The Role of Platelets in Sickle Cell Disease. , 2019, , 563-580.		2

#	ARTICLE	IF	CITATIONS
844	Cerebral Thromboembolism after Lobectomy for Lung Cancer: Pathological Diagnosis and Mechanism of Thrombus Formation. <i>Cancers</i> , 2019, 11, 488.	1.7	11
845	Thromboelastographic platelet mapping in dogs with complicated <i>Babesia rossi</i> infection. <i>Veterinary Clinical Pathology</i> , 2019, 48, 11-18.	0.3	3
846	Platelets retain inducible alpha granule secretion by P-Selectin expression but exhibit mechanical dysfunction during trauma-induced coagulopathy. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 771-781.	1.9	24
847	Physiology of haemostasis. <i>Anaesthesia and Intensive Care Medicine</i> , 2019, 20, 152-158.	0.1	19
848	Potential role of activated factor VIII (FVIIIa) in FVIIa/tissue factor-dependent FXa generation in initiation phase of blood coagulation. <i>International Journal of Hematology</i> , 2019, 109, 390-401.	0.7	4
849	Hemostasis, Surgical Bleeding, and Transfusion. , 2019, , 41-53.		2
850	1. Grundlagen der Blutgerinnung. , 2019, , 1-14.		0
851	Epicatechin influences primary hemostasis, coagulation and fibrinolysis. <i>Food and Function</i> , 2019, 10, 7291-7298.	2.1	24
852	It's About Time: Transfusion effects on postinjury platelet aggregation over time. <i>Journal of Trauma and Acute Care Surgery</i> , 2019, 87, 1042-1051.	1.1	18
853	Endothelial glycocalyx in acute care surgery – what anaesthesiologists need to know for clinical practice. <i>BMC Anesthesiology</i> , 2019, 19, 238.	0.7	29
854	Assessment and management of coagulopathy in critically-ill patients with liver failure. <i>Current Opinion in Critical Care</i> , 2019, 25, 179-186.	1.6	22
855	Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications. <i>Anesthesia and Analgesia</i> , 2019, 129, 762-773.	1.1	95
856	Overview of the Coagulation System. , 2019, , 559-564.		8
857	Autoimmune Aspects of Kawasaki Disease. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019, 29, 251-261.	0.6	65
858	Dynamic evaluation of hemostasis in the acute phase of Kawasaki disease using comprehensive coagulation functional assays. <i>Thrombosis Research</i> , 2019, 174, 76-83.	0.8	21
859	Enhancement of hemostatic property of plant derived oxidized nanocellulose-silk fibroin based scaffolds by thrombin loading. <i>Carbohydrate Polymers</i> , 2019, 208, 168-179.	5.1	44
860	Management of Cardiopulmonary Bypass-Associated Coagulopathy. , 2019, , 213-230.		0
861	Bleeding Complications After Cardiac Arrest and Targeted Temperature Management, a Post Hoc Study of the Targeted Temperature Management Trial. <i>Therapeutic Hypothermia and Temperature Management</i> , 2019, 9, 177-183.	0.3	12

#	ARTICLE	IF	CITATIONS
862	Coagulation Disorders in Congenital Heart Disease. , 2019, , 282-302.e7.		0
863	A new dynamic model for in vitro evaluation of intravascular devices. International Journal of Artificial Organs, 2019, 42, 42-48.	0.7	1
864	The correlation between conventional coagulation tests and thromboelastography in each phase of liver transplantation. Clinical Transplantation, 2019, 33, e13478.	0.8	10
865	Regulation of Hemostasis and Thrombosis. , 2019, , 81-89.e2.		0
866	Anticoagulation. , 2019, , 368-378.e2.		1
867	Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 2â€™ Defining rational therapeutic usage. Journal of Veterinary Emergency and Critical Care, 2019, 29, 49-59.	0.4	31
868	Feeling the Force: Measurements of Platelet Contraction and Their Diagnostic Implications. Seminars in Thrombosis and Hemostasis, 2019, 45, 285-296.	1.5	22
869	Blood and Coagulation. , 2019, , 837-848.		0
871	Pediatric Critical Care. , 2019, , .		3
872	Absences of Endothelial Microvesicle Changes in the Presence of the Endotheliopathy of Trauma. Shock, 2019, 51, 180-184.	1.0	9
873	The influence of cerebrospinal fluid on blood coagulation and the implications for ventriculovenous shunting. Journal of Neurosurgery, 2019, 130, 1244-1251.	0.9	7
874	The 3.2 Å... structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain. Journal of Thrombosis and Haemostasis, 2020, 18, 57-69.	1.9	15
875	From multi-target anticoagulants to DOACs, and intrinsic coagulation factor inhibitors. Blood Reviews, 2020, 39, 100615.	2.8	35
876	Prospective Longitudinal Evaluation of Coagulation with Novel Thromboelastography Technology in Patients After Subarachnoid Hemorrhage: A Pilot Study. World Neurosurgery, 2020, 136, e181-e195.	0.7	6
877	TEGÂ®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care. Platelets, 2020, 31, 932-938.	1.1	12
878	Alternative Complement Pathway Activation Provokes a Hypercoagulable State with Diminished Fibrinolysis. Shock, 2020, 53, 560-565.	1.0	11
879	A comprehensive review of topical hemostatic agents: The good, the bad, and the novel. Journal of Trauma and Acute Care Surgery, 2020, 88, e1-e21.	1.1	60
880	Endoscopic activity, tissue factor and Crohnâ€™s disease: findings in clinical remission patients. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093941.	1.4	2

#	ARTICLE	IF	CITATIONS
881	How to Capture the Bleeding Phenotype in FXI-Deficient Patients. <i>Hamostaseologie</i> , 2020, 40, 491-499.	0.9	5
882	Coagulation Homeostasis in Liver Disease. <i>Clinical Liver Disease</i> , 2020, 16, 137-141.	1.0	7
883	<i>Yersinia pestis</i> Plasminogen Activator. <i>Biomolecules</i> , 2020, 10, 1554.	1.8	12
884	Assessment of Aptamer-Targeted Contrast Agents for Monitoring of Blood Clots in Computed Tomography and Fluoroscopy Imaging. <i>Bioconjugate Chemistry</i> , 2020, 31, 2737-2749.	1.8	7
885	Platelet Imaging. , 2020, , .		0
886	The interaction between the complement system and hemostatic factors. <i>Current Opinion in Hematology</i> , 2020, 27, 341-352.	1.2	20
887	Point-of-Care Diagnostics in Coagulation Management. <i>Sensors</i> , 2020, 20, 4254.	2.1	26
888	MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1301-1312.	1.0	10
889	Dynamic effects of calcium on in vivo and ex vivo platelet behavior after trauma. <i>Journal of Trauma and Acute Care Surgery</i> , 2020, 89, 871-879.	1.1	15
890	Computationally Driven Discovery in Coagulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 79-86.	1.1	4
891	Effects of thrombomodulin alfa on hemostatic parameters in disseminated intravascular coagulation: Post hoc analysis of a phase 3 randomized controlled trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1141-1149.	1.0	5
892	Use of Thromboelastography in Clinical Practice. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2020, 50, 1397-1409.	0.5	26
893	The Use of Antithrombotics in Critical Illness. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2020, 50, 1351-1370.	0.5	0
894	Polymeric Hydrogel Systems as Emerging Biomaterial Platforms to Enable Hemostasis and Wound Healing. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000905.	3.9	194
895	Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095428.	0.7	32
896	Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 622473.	1.1	69
897	Reference Values of Thrombolastometry Parameters in Healthy Term Neonates. <i>Children</i> , 2020, 7, 259.	0.6	10
898	Managing microvesicles or Virchow's vicissitude. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 696-697.	0.4	4

#	ARTICLE	IF	CITATIONS
899	Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system. <i>Blood Advances</i> , 2020, 4, 5501-5511.	2.5	20
900	Coagulation factor activity patterns of venom-induced consumption coagulopathy in naturally occurring tiger snake (<i>Notechis scutatus</i>) envenomed dogs treated with antivenom. <i>Toxicon</i> , 2020, 181, 36-44.	0.8	1
901	Reduction of Halitosis by a Tablet Containing <i>Weissella cibaria</i> CMU: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of Medicinal Food</i> , 2020, 23, 649-657.	0.8	25
902	Hydroxyapatite as a biomaterial "a gift that keeps on giving. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 1035-1062.	0.9	64
903	Phosphatidylserine positive microparticles improve hemostasis in in-vitro hemophilia A plasma models. <i>Scientific Reports</i> , 2020, 10, 7871.	1.6	11
904	Physiological roles of transverse lipid asymmetry of animal membranes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2020, 1862, 183382.	1.4	60
905	A Novel Microchip Flow Chamber (Total Thrombus Analysis System) to Assess Canine Hemostasis. <i>Frontiers in Veterinary Science</i> , 2020, 7, 307.	0.9	2
906	Coagulation, hemostasis, and transfusion during liver transplantation. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2020, 34, 79-87.	1.7	18
907	Thrombin generation and bleeding in cardiac surgery: a clinical narrative review. <i>Canadian Journal of Anaesthesia</i> , 2020, 67, 746-753.	0.7	11
908	Acquired hemophilia A: when an overlooked autoimmune disorder causes significant bleeding. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 79-89.	0.5	1
909	Biological mechanisms and individual variation in fibrinolysis after major trauma. <i>Emergency Medicine Journal</i> , 2020, 37, 135-140.	0.4	13
910	Diagnosis and Treatment of Trauma-Induced Coagulopathy by Viscoelastography. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 134-146.	1.5	33
911	Whole Blood for Civilian Urban Trauma Resuscitation: Historical, Present, and Future Considerations. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 221-234.	1.5	12
912	A novel assay for studying the involvement of blood cells in whole blood thrombin generation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1291-1301.	1.9	16
913	A journey upstream: Fluctuating platelet-specific genes in cell-free plasma as proof-of-concept for using ribonucleic acid sequencing to improve understanding of postinjury platelet biology. <i>Journal of Trauma and Acute Care Surgery</i> , 2020, 88, 742-751.	1.1	6
914	Identification of injury and shock driven effects on ex vivo platelet aggregometry: A cautionary tale of phenotyping. <i>Journal of Trauma and Acute Care Surgery</i> , 2020, 89, 20-28.	1.1	18
915	The Developing Balance of Thrombosis and Hemorrhage in Pediatric Surgery: Clinical Implications of Age-Related Changes in Hemostasis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962092909.	0.7	26
916	Thromboinflammation in COVID-19 acute lung injury. <i>Paediatric Respiratory Reviews</i> , 2020, 35, 20-24.	1.2	60

#	ARTICLE	IF	CITATIONS
917	Impaired platelet-dependent thrombin generation associated with thrombocytopenia is improved by prothrombin complex concentrates in vitro. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 334-342.	1.0	4
918	Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 834-843.	1.9	22
919	Inhibitors of blood coagulation factor XIII. <i>Analytical Biochemistry</i> , 2020, 605, 113708.	1.1	16
920	Advances in managing rare acquired bleeding disorders. <i>Expert Review of Hematology</i> , 2020, 13, 599-606.	1.0	4
921	The Role of Endotheliocytes of Liver Sinusoid Capillaries in the Pathogenesis of Disorders in the Vascular-Platelet Link of Hemostasis in the Acute Period of Traumatic Brain Injury. <i>Cell and Tissue Biology</i> , 2020, 14, 43-51.	0.2	0
922	Characterization of blood coagulation dynamics and oxygenation in <i>ex vivo</i> retinal vessels by fluorescence hyperspectral imaging. <i>Journal of Biophotonics</i> , 2020, 13, e202000021.	1.1	1
923	Tissue Factor-Independent Coagulation Correlates with Clinical Phenotype in Factor XI Deficiency and Replacement Therapy. <i>Thrombosis and Haemostasis</i> , 2021, 121, 150-163.	1.8	5
925	Risk of bleeding during oral surgery in patients with liver cirrhosis. <i>Journal of the American Dental Association</i> , 2021, 152, 46-54.e2.	0.7	3
926	Protease-activated receptor 1 as a potential therapeutic target for COVID-19. <i>Experimental Biology and Medicine</i> , 2021, 246, 688-694.	1.1	19
927	Hemostatic defects in massive transfusion: an update and treatment recommendations. <i>Expert Review of Hematology</i> , 2021, 14, 219-239.	1.0	15
928	Administering DVT Prophylaxis Sooner Than 48 Hours Does Not Increase Failure of Nonoperative Management of High-Grade (Grades III-V) Splenic Injuries. <i>American Surgeon</i> , 2021, 87, 527-531.	0.4	4
929	Theranostic applications of stimulus-responsive systems based on carbon dots. <i>International Journal of Polymeric Materials and Polymeric Biomaterials</i> , 2021, 70, 117-130.	1.8	4
930	Whole Blood, Fixed Ratio, or Goal-Directed Blood Component Therapy for the Initial Resuscitation of Severely Hemorrhaging Trauma Patients: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 320.	1.0	19
932	Association between Circulating Protein C Levels and Incident Dementia: The Atherosclerosis Risk in Communities Study. <i>Neuroepidemiology</i> , 2021, 55, 306-315.	1.1	2
933	Evolving science of trauma-induced coagulopathy. <i>International Anesthesiology Clinics</i> , 2021, 59, 25-30.	0.3	2
934	Effects of storage time and temperature on thromboelastographic analysis in dogs and horses. <i>Veterinary Clinical Pathology</i> , 2021, 50, 9-19.	0.3	3
935	Phosphatidylserine and phosphatidylethanolamine regulate the structure and function of FVIIa and its interaction with soluble tissue factor. <i>Bioscience Reports</i> , 2021, 41, .	1.1	0
936	Enfermedades congénitas de la coagulación y manejo en Odontopediatría. <i>Revista De Odontopediatría Latinoamericana</i> , 2021, 2, 7.	0.0	0

#	ARTICLE	IF	CITATIONS
937	Accidentally discovered high INR in pregnancy unmasks an inherited factor VII (FVII) deficiency that is paradoxically associated with thrombotic tendency. <i>BMJ Case Reports</i> , 2021, 14, e237781.	0.2	4
938	Fibrinogen Early In Severe Trauma study (FEISTY): results from an Australian multicentre randomised controlled pilot trial. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2021, 23, 32-46.	0.0	4
939	Endotheliopathy in septic conditions: mechanistic insight into intravascular coagulation. <i>Critical Care</i> , 2021, 25, 95.	2.5	31
941	Added Value of Blood Cells in Thrombin Generation Testing. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1574-1587.	1.8	13
942	Trauma-Induced Coagulopathy: Overview of an Emerging Medical Problem from Pathophysiology to Outcomes. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 16.	0.7	20
944	Hypercoagulopathy, acquired coagulation disorders and anticoagulation before, during and after extracorporeal membrane oxygenation in COVID-19: a case series. <i>Perfusion (United Kingdom)</i> , 2021, 36, 592-602.	0.5	11
945	Multidimensional flow cytometry reveals novel platelet subpopulations in response to prostacyclin. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1800-1812.	1.9	11
946	Haemostasis. <i>Medicine</i> , 2021, 49, 199-204.	0.2	1
947	Fibrinolysis and Remote Ischemic Conditioning: Mechanisms and Treatment Perspectives in Stroke. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 610-620.	1.5	2
948	Trauma-induced coagulopathy. <i>Nature Reviews Disease Primers</i> , 2021, 7, 30.	18.1	300
949	Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study. <i>Journal of the American Heart Association</i> , 2021, 10, e019644.	1.6	12
950	CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1932-1947.	1.9	7
951	Assessment of laboratory tests and intraoperative bleeding in patients with liver cirrhosis undergoing tooth extractions. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2022, 133, 148-155.	0.2	3
952	Understanding and managing the complex balance between bleeding and thrombosis following cardiopulmonary bypass in paediatric cardiac surgical patients. <i>Cardiology in the Young</i> , 2021, 31, 1251-1257.	0.4	2
953	The Role of Anesthetic Selection in Perioperative Bleeding. <i>BioMed Research International</i> , 2021, 2021, 1-6.	0.9	2
954	Factor Xa inhibitors: critical considerations for clinical development and testing. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 397-402.	1.0	4
955	The use of thromboelastography (TEG) and rotational thromboelastometry (ROTEM) in neonates: a systematic review. <i>European Journal of Pediatrics</i> , 2021, 180, 3455-3470.	1.3	26
956	Viscoelastic tests in liver disease: where do we stand now?. <i>World Journal of Gastroenterology</i> , 2021, 27, 3290-3302.	1.4	16

#	ARTICLE	IF	CITATIONS
957	Haemophilia. Nature Reviews Disease Primers, 2021, 7, 45.	18.1	103
958	Fibrinogen in traumatic haemorrhage. Current Opinion in Anaesthesiology, 2021, 34, 514-520.	0.9	9
960	Diagnostic utility of flow cytometry based coated platelets assay as a biomarker to predict thrombotic or hemorrhagic phenotype in acute stroke. Cytometry Part B - Clinical Cytometry, 2022, 102, 246-253.	0.7	5
961	Global Thrombosis Test: Occlusion by Coagulation or SIPA?. TH Open, 2021, 05, e400-e410.	0.7	4
962	Platelet-Therapeutics to Improve Tissue Regeneration and Wound Healing”Physiological Background and Methods of Preparation. Biomedicines, 2021, 9, 869.	1.4	14
963	Extracellular vesicle-associated procoagulant activity is highest the first 3 hours after trauma and thereafter declines substantially: A prospective observational pilot study. Journal of Trauma and Acute Care Surgery, 2021, 91, 681-691.	1.1	4
964	Retrospective review of 27 European cases of fatal elephant endotheliotropic herpesvirus-haemorrhagic disease reveals evidence of disseminated intravascular coagulation. Scientific Reports, 2021, 11, 14173.	1.6	11
965	Rotational thromboelastometry reduces blood loss and blood product usage after lung transplantation. Journal of Heart and Lung Transplantation, 2021, 40, 631-641.	0.3	15
966	Bioinspired artificial platelets: past, present and future. Platelets, 2022, 33, 35-47.	1.1	16
967	Biomaterial and cellular implants: foreign surfaces where immunity and coagulation meet. Blood, 2022, 139, 1987-1998.	0.6	17
968	Clinical Strategies Against Early Hematoma Expansion Following Intracerebral Hemorrhage. Frontiers in Neuroscience, 2021, 15, 677744.	1.4	9
969	Pathophysiology of Trauma-Induced Coagulopathy. Transfusion Medicine Reviews, 2021, 35, 80-86.	0.9	20
970	Binding of the Andes Virus Nucleocapsid Protein to RhoGDI Induces the Release and Activation of the Permeability Factor RhoA. Journal of Virology, 2021, 95, e0039621.	1.5	0
971	Blood Conservation and Hemostasis Management in Pediatric Cardiac Surgery. Frontiers in Cardiovascular Medicine, 2021, 8, 689623.	1.1	5
973	Advances in the management of haemophilia: emerging treatments and their mechanisms. Journal of Biomedical Science, 2021, 28, 64.	2.6	18
974	Scratching the Surface. Advances in Anesthesia, 2021, 39, 35-51.	0.5	5
975	Bleeding and Thrombosis: Insights into Pathophysiology of Bothrops Venom-Related Hemostasis Disorders. International Journal of Molecular Sciences, 2021, 22, 9643.	1.8	27
976	High Mutational Heterogeneity, and New Mutations in the Human Coagulation Factor V Gene. Future Perspectives for Factor V Deficiency Using Recombinant and Advanced Therapies. International Journal of Molecular Sciences, 2021, 22, 9705.	1.8	9

#	ARTICLE	IF	CITATIONS
977	Potential use of plants and their extracts in the treatment of coagulation disorders in COVID-19 disease: a narrative review. <i>Longhua Chinese Medicine</i> , 0, 4, 26-26.	0.5	2
978	TEGÂ® and ROTEMÂ® Traces: Clinical Applications of Viscoelastic Coagulation Monitoring in Neonatal Intensive Care Unit. <i>Diagnostics</i> , 2021, 11, 1642.	1.3	8
979	Use of rotational thromboelastometry (ROTEMÂ®) to predict thrombotic complications of microvascular head and neck reconstruction. <i>Oral Oncology</i> , 2021, 124, 105515.	0.8	1
980	Management of factor XI deficiency in oncological liver and colorectal surgery by therapeutic plasma exchange: A case report. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103176.	0.5	3
981	Aptamers for Thrombotic Diseases. , 2021, , 279-318.		0
983	Role of Tissue Factor in the Pathogenesis of COVID-19 and the Possible Ways to Inhibit It. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110039.	0.7	21
984	Point-of-Care Coagulation Monitoring. , 2014, , 329-342.		1
986	Cell-Mediated Hemostasis. , 2021, , 31-41.		1
987	Factor VIII and Factor V Membrane Bound Complexes. <i>Sub-Cellular Biochemistry</i> , 2021, 96, 153-175.	1.0	4
988	Colonoscopy. , 2015, , 41-112.		1
989	Biomaterials-Based Strategies in Blood Substitutes. , 2015, , 113-137.		1
990	Cell-Mediated Hemostasis. , 2016, , 3-14.		2
992	Hemostasis and Anticoagulation Therapy. , 2017, , 47-68.		2
993	Split Blood Products. , 2015, , 151-175.		1
994	Pathophysiology of Neonatal Disseminated Intravascular Coagulation and Thrombosis. , 2004, , 1460-1473.		2
995	Core Topics in Critical Care Medicine. , 2010, , .		2
1000	Tissue factor. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 521-538.	0.5	66
1001	Active, Personalized, and Balanced Coagulation Management Saves Lives in Patients with Massive Bleeding. <i>Anesthesiology</i> , 2010, 113, 1016-1018.	1.3	23

#	ARTICLE	IF	CITATIONS
1002	A Prospective Study of the Association Between Clinically Significant Bleeding in PICU Patients and Thrombocytopenia or Prolonged Coagulation Times*. <i>Pediatric Critical Care Medicine</i> , 2017, 18, e455-e462.	0.2	11
1003	Damage control resuscitation for patients with major trauma. <i>BMJ: British Medical Journal</i> , 2009, 338, b1778-b1778.	2.4	207
1004	Intravascular hemolysis triggers ADP-mediated generation of platelet-rich thrombi in precapillary pulmonary arterioles. <i>JCI Insight</i> , 2020, 5, .	2.3	8
1005	Binding of Thrombin-Activated Platelets to a Fibrin Scaffold through α IIb β 3 Evokes Phosphatidylserine Exposure on Their Cell Surface. <i>PLoS ONE</i> , 2013, 8, e55466.	1.1	19
1006	IgM-Enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis: A Before-After Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0160907.	1.1	22
1007	The System of Blood Coagulation in Normal and in Liver Transplantation (Review). <i>Obshchaya Reanimatologiya</i> , 2018, 14, 58-84.	0.2	11
1008	Platelets: an outlook from biology through evidence-based achievements in critical care. <i>Annals of Translational Medicine</i> , 2017, 5, 449-449.	0.7	6
1009	The velocity curve of the clotting waveform of rotational thromboelastometry predicts bleeding after cardiac surgery but conventional rotational thromboelastometric parameters do not. <i>Minerva Anesthesiologica</i> , 2019, 85, 505-513.	0.6	4
1010	In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor. <i>Blood Transfusion</i> , 2014, 12, 78-84.	0.3	18
1011	Beyond Thrombosis: the Role of Platelets in Pulmonary Hypertension. <i>SciMedicine Journal</i> , 2020, 2, 243-271.	1.5	20
1012	A case of intracranial hemorrhage in a neonate with congenital factor VII deficiency. <i>Korean Journal of Pediatrics</i> , 2010, 53, 913.	1.9	5
1013	Advances in the treatment of hemorrhagic stroke: a possible new treatment.. <i>Cleveland Clinic Journal of Medicine</i> , 2005, 72, 341-344.	0.6	8
1014	Nuevos anticoagulantes orales. <i>Revista Medica De Chile</i> , 2011, 139, 1347-1355.	0.1	8
1015	Establishing a normal reference range for thromboelastography in North Indian healthy volunteers. <i>Indian Journal of Pathology and Microbiology</i> , 2014, 57, 43.	0.1	26
1016	Amniotic fluid embolism: literature review and an integrated concept of pathomechanism. <i>Open Journal of Obstetrics and Gynecology</i> , 2011, 01, 178-183.	0.1	10
1017	Hemostasis: A Cell Based Model. <i>Journal of Physiology and Pharmacology Advances</i> , 2015, 5, 638.	0.1	1
1018	A case of acquired hemophilia diagnosed incidentally on postoperative bleeding after tooth extraction. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2006, 52, 733-737.	0.0	2
1019	Fabrication of thrombin loaded TEMPO-oxidized cellulose nanofiber-gelatin sponges and their hemostatic behavior in rat liver hemorrhage model. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2022, 33, 499-516.	1.9	9

#	ARTICLE	IF	CITATIONS
1020	Bioactive Natural Compounds with Antiplatelet and Anticoagulant Activity and Their Potential Role in the Treatment of Thrombotic Disorders. <i>Life</i> , 2021, 11, 1095.	1.1	12
1021	Variations in clot phenotype following injury: The MA-R ratio and fragile clots. <i>Journal of Trauma and Acute Care Surgery</i> , 2022, 92, 504-510.	1.1	3
1023	Endogenous Thrombin Potential in Platelet-Rich Plasma " New Insights Regarding the Different Action of FVIII and FIX. , 2004, , 87-93.		0
1025	Thrombotic Vascular Disease. , 2005, , 451-471.		0
1026	Disorders of Coagulation. , 2005, , 811-832.		0
1029	Clinical and Research Applications of Markers of Thrombosis. , 2006, , 451-466.		0
1031	7. Diagnosis and management of acquired hemophilia and acquired von Willebrand disease. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2007, 18, 575-579.	0.1	0
1032	Hemorrhagic diatheses. , 2007, , 311-324.		0
1033	Rationale for direct factor Xa inhibitors in acute coronary syndromes. , 2007, , 119-126.		1
1034	έπεί/4ήμ,,æ·ã·æ´æ€\$áz·è¡€æη²ά†ά·ºç¬¬Vllá·άè£½á%ã®ά†ºè¡€æ€\$ç—...æ...ã·ã®άζœç””·â€”ç†è«—ã·ç\$‘á çš,,ά®ÿœμâ€”. <i>Journal of the</i>		0
1035	The use of recombinant factor VIIa in the treatment of bleeding disorders: current and future perspective. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2008, 19, 422-429.	0.1	1
1036	Recombinant Factor VIIa for Bleeding in Non-hemophiliac Pediatric Patients. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2009, 14, 38-47.	0.3	1
1037	Perioperative Management of Hemostasis and Thrombosis in Cardiovascular Anesthesia. <i>The Journal of Japan Society for Clinical Anesthesia</i> , 2009, 29, 809-814.	0.0	0
1038	Medications for Hemostasis. , 2009, , 421-437.		0
1039	HÄmatologie. , 2009, , 461-570.		0
1040	Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. , 2009, , 293-340.		2
1041	Bleeding and Hemostasis. , 2010, , 181-196.		0
1042	Coagulation and fibrinolytic responses at an early phase of trauma: The main issues in the world are reviewed and discussed. <i>Nihon Kyukyu Igakukai Zasshi</i> , 2010, 21, 765-778.	0.0	1

#	ARTICLE	IF	CITATIONS
1043	Mikropartikel. , 2010, , 89-95.		0
1045	Assessment of Thrombin Generation. European Oncology and Haematology, 2010, 00, 16.	0.0	0
1046	Zerebrovaskuläre Notfälle. , 2011, , 655-667.		0
1047	Goal-directed Coagulation Management in Major Trauma. Annual Update in Intensive Care and Emergency Medicine, 2011, , 611-627.	0.1	0
1048	Antiplatelet Therapy. , 2011, , 201-221.		0
1050	A New Understanding of Coagulopathy in Trauma. , 2012, , 689-698.		0
1051	Introduction of Postoperative Cases in Which Diagnosis and Treatment were Difficult in ICU. The Journal of Japan Society for Clinical Anesthesia, 2012, 32, 507-512.	0.0	0
1053	Inborn Defects of the Coagulative System. , 2012, , 73-84.		0
1055	Epidural Analgesia - Current Views and Approaches. , 2012, , .		3
1056	Aetiology of Deep Venous Thrombosis - Implications for Prophylaxis. , 0, , .		0
1057	Novos conceitos sobre a fisiologia da hemostasia. Revista Da Universidade Vale Do Rio Verde, 2012, 10, 218-233.	0.1	1
1058	Use of Recombinant Factor Seven (rFVIIa) in the treatment of severe bleeding from trauma. The Sri Lanka Journal of Surgery, 2012, 30, 9.	0.0	0
1059	Correlation between Inflammation and Fibrinolysis in Hypertensive Centrally Obese Subjects: A Study on C-Reactive Protein, Plasminogen Activator Inhibitor-1 and Thrombin Activatable Fibrinolysis Inhibitor. Indonesian Biomedical Journal, 2012, 4, 151.	0.2	0
1060	Associated Risk of Recombinant Activated Factor VIIa Application. Heart Surgery Forum, 2013, 16, 132.	0.2	0
1061	Shock and Coagulopathy. , 2014, , 259-296.		0
1062	Laboratory Analysis of Coagulation. , 2014, , 1-37.		0
1063	Factor VIII: New mechanism of the coagulant regulation of FVIII and activated protein C/protein S. Japanese Journal of Thrombosis and Hemostasis, 2014, 25, 449-457.	0.1	0
1064	Acute coagulopathy of trauma: Mechanism, monitoring, management. World Journal of Anesthesiology, 2014, 3, 111.	0.5	0

#	ARTICLE	IF	CITATIONS
1066	Transfusionsmanagement bei Notfall- und Massivtransfusionen. , 2014, , 83-113.		0
1067	Thromboembolic Disorders in the PICU. , 2014, , 327-340.		0
1068	Coagulation, Anticoagulation, and Inflammatory Response. , 2014, , 77-90.		1
1069	Anticoagulación estratificada por riesgos. Revista Universitas Medica, 2016, 55, 390-406.	0.0	0
1070	Hämostase, Hämotherapie und Lyse. , 2015, , 479-509.		0
1072	Hämostase. , 2015, , 1-48.		0
1073	Managing coagulopathy and thromboprophylaxis in the neurosurgical patient. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2015, 15, 11-16.	0.1	0
1074	Thrombin-Antithrombin System. , 2016, , 15-29.		0
1075	Physiologie und Pathophysiologie der Blutgerinnung. , 2016, , 15-24.		0
1076	Management of Chronically Anticoagulated Patients. , 2016, , 529-542.		0
1077	Thrombocytopenia in the Surgical Intensive Care Unit. , 2016, , 327-333.		0
1078	Abstract 34: Impact of Thrombomodulin and Thrombin-activatable Fibrinolysis Inhibitor on the Anti-coagulant and Pro-fibrinolytic Effects of Rivaroxaban. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, .	1.1	1
1079	Thromboplastic Activity of Erythrocytes After Freeze-Thawing in Combined Media. Problems of Cryobiology and Cryomedicine, 2016, 26, 229-237.	0.3	0
1081	Coagulation Monitoring. , 2017, , 433-443.		0
1082	Effects of rivaroxaban on intimal hyperplasia and smooth muscle cell proliferation at the carotid artery anastomosis site in rabbits. Anatolian Journal of Cardiology, 2017, 18, 261-265.	0.5	4
1083	Impact of the Diabetic State on Wound Healing Dynamics and Expression of Soluble Cellular Mediators. , 2017, , 3-16.		0
1085	15th International Congress on Antiphospholipid Antibodies Task Force on Pediatric Antiphospholipid Syndrome Report. , 2017, , 291-306.		1
1087	Blood Coagulation During Sepsis and Septic Shock: Is There Still Room for Anticoagulants?. , 2018, , 43-76.		0

#	ARTICLE	IF	CITATIONS
1088	Cesarean Delivery Complications and Cesarean Hysterectomy. , 2017, , 72-79.		0
1090	Normal Labor. , 2017, , 1-12.		0
1091	Management of Obstetric Umbilical Cord Complications. , 2017, , 42-49.		0
1093	Placental Abnormalities. , 2017, , 32-41.		0
1094	Operative Vaginal Delivery. , 2017, , 50-63.		0
1095	Induction and Augmentation of Labor. , 2017, , 23-31.		0
1096	Coagulation Enzymes Review and Review of Hemostasis: Putting It All Together. , 2018, , 13-23.		0
1097	Laboratory Assessment of Coagulation. , 2018, , 353-359.		0
1098	Rotational thromboelastometry in therapy of life threatening bleeding. Vnitri Lekarstvi, 2018, 64, 380-383.	0.1	0
1100	Current Insights on the Etiology and Pathogenesis of Venous Thrombosis: Virchow's Triad Revision. Flebologiya, 2019, 13, 227.	0.2	5
1101	Coagulation Derangements in the ACS Patient: Understanding and Addressing Acute Coagulopathy. Hot Topics in Acute Care Surgery and Trauma, 2019, , 195-218.	0.1	0
1102	Understanding of pathophysiology of thrombosis and prediction of the efficacy of medicine using simulation approach. Japanese Journal of Thrombosis and Hemostasis, 2019, 30, 856-861.	0.1	0
1103	Fall 24“ Die Sache hrt auf. , 2019, , 365-380.		0
1104	Rheumatoid arthritis: some components of hemostasis and inflammation. Sovremennaya Revmatologiya, 2019, 13, 87-94.	0.1	4
1105	Modern view on hemostasis system: cell theory. Meditsinskiy Sovet, 2019, , 72-77.	0.1	7
1106	Coagulation and Anticoagulants. , 2020, , 1-53.		0
1108	Loeffler’s Endocarditis and Hypereosinophilic Syndrome. Cardiology in Review, 2021, 29, 150-155.	0.6	5
1109	Usefulness of perioperative rotational thrombelastometry during scoliosis surgery in children. Journal of Neurosurgery: Spine, 2020, 32, 865-870.	0.9	5

#	ARTICLE	IF	CITATIONS
1110	Hemophilia and fibrinolysis system. Japanese Journal of Thrombosis and Hemostasis, 2020, 31, 366-372.	0.1	1
1111	Utility of rotational thromboelastometry in total hip replacement revision surgery (case-control) Tj ETQq1 1 0.784314 rgBT /Qverlock 10 0.4 2	0.4	2
1112	Physiological Haemostasis. , 2020, , 199-213.		0
1115	Analysis of hemostatic changes in haemodilution and blood loss. Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya, 2020, , 55.	0.2	0
1116	Clinical Practice Guideline for the Treatment of Traumatic Shock Patients from the Korean Society of Traumatology. Journal of Trauma and Injury, 2020, 33, 1-12.	0.2	3
1117	Is recombinant activated factor seven effective for haematemesis in patients with cirrhotic liver disease?. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 2005, 16, 187-190.	0.1	0
1118	Hemophilia A and Inhibitors. , 2008, , 389-405.		0
1123	Management of Chronically Anticoagulated Patients. , 2021, , 663-676.		0
1124	Synthetic Blood Substitutes. , 2021, , 719-743.		1
1126	Platelets. , 2021, , 85-99.		0
1127	Study of the effect of the concentration of sodium carboxymethylcellulose on hemostatic and antiadhesive activity during liver operations in an experiment. SeÄenovskij Vestnik, 2020, 11, 4-14.	0.3	2
1129	Plasmatic and cell components of hemostasis in patients with serious burned wounds: studying at early period of disease. Medical Alphabet, 2020, , 56-60.	0.0	0
1130	Use of rotational thromboelastometry in perioperative medicine and its comparison with standard coagulation testing. Anesteziolog A Intenzivni Medicina, 2020, 31, 238-245.	0.1	0
1131	Disorders of coagulation. , 2022, , 287-340.		1
1132	Blood Coagulation Algorithm: A Novel Bio-Inspired Meta-Heuristic Algorithm for Global Optimization. Mathematics, 2021, 9, 3011.	1.1	10
1133	Comparative study of the effect of tranexamic acid and exogenous fibrin monomer on fibrin formation in the injury area during stimulation of fibrinolysis by streptokinase. Gematologiya I Transfuziologiya, 2021, 66, 556-566.	0.1	0
1134	Developmental hemostasis in the neonatal period. World Journal of Pediatrics, 2022, 18, 7-15.	0.8	7
1135	Physiology of haemostasis. Anaesthesia and Intensive Care Medicine, 2022, 23, 111-117.	0.1	1

#	ARTICLE	IF	CITATIONS
1136	Platelet-mimicking procoagulant nanoparticles augment hemostasis in animal models of bleeding. <i>Science Translational Medicine</i> , 2022, 14, eabb8975.	5.8	35
1137	The role of phosphatidylserine on the membrane in immunity and blood coagulation. <i>Biomarker Research</i> , 2022, 10, 4.	2.8	30
1138	Diagnosis and management of new onset severe coagulopathy during <scp>afterâ€hours</scp> with thromboelastography. <i>American Journal of Hematology</i> , 2022, 97, 375-382.	2.0	1
1139	Trauma-induced coagulopathy: Mechanisms and clinical management. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 40-48.	0.2	3
1140	Low Bone Mineral Density in Hemophiliacs. <i>Frontiers in Medicine</i> , 2022, 9, 794456.	1.2	15
1141	The correlation of Dâ€dimer to stroke diagnosis within 24Âhours: A metaâ€analysis. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24271.	0.9	3
1142	Usefulness of thromboelastography for perioperative evaluation of hemostatic profile in patients with primary brain tumors undergoing surgery. <i>Anesthesia: Essays and Researches</i> , 2021, 15, 279.	0.2	0
1143	Basic aspect of emicizumab. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2022, 33, 4-13.	0.1	0
1144	Siteâ€specific functional roles of the Factor X activation peptide in the intrinsic tenaseâ€mediated Factor X activation. <i>FEBS Letters</i> , 2022, 596, 1567-1575.	1.3	3
1145	Hemostatic Dysfunction in Dogs Naturally Infected with <i>Angiostrongylus vasorum</i> â€A Narrative Review. <i>Pathogens</i> , 2022, 11, 249.	1.2	8
1146	Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial. <i>BMJ Open</i> , 2022, 12, e056922.	0.8	3
1148	Efficacy of platelet transfusion in cardiac surgery. <i>Platelets</i> , 2022, 33, 987-997.	1.1	5
1149	Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1290-1300.	1.9	19
1150	Do not forget the platelets: The independent impact of red blood cell to platelet ratio on mortality in massively transfused trauma patients. <i>Journal of Trauma and Acute Care Surgery</i> , 2022, 93, 21-29.	1.1	9
1152	Dynamic use of fibrinogen under viscoelastic assessment results in reduced need for plasma and diminished overall transfusion requirements in severe trauma. <i>Journal of Trauma and Acute Care Surgery</i> , 2022, 93, 166-175.	1.1	5
1153	Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective. <i>Biophysical Reviews</i> , 2022, 14, 427-461.	1.5	8
1154	Retrospective examination of coagulation parameters in 33 patients with autoimmune coagulation factor deficiencies in Japan: A single-center analysis. <i>Thrombosis Research</i> , 2022, 213, 154-162.	0.8	5
1155	Comparison of the effects of open-tube and evacuated tubeâ€assisted sampling methods on thromboelastography variables for blood samples from healthy dogs. <i>American Journal of Veterinary Research</i> , 2022, 83, 239-244.	0.3	0

#	ARTICLE	IF	CITATIONS
1157	Platelet-inspired nanomedicine in hemostasis thrombosis and thromboinflammation. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1535-1549.	1.9	23
1158	Point of care coagulation management in anesthesiology and critical care. <i>Minerva Anestesiologica</i> , 2022, 88, .	0.6	6
1159	The role of procoagulant phospholipids on the surface of circulating blood cells in thrombosis and haemostasis. <i>Open Biology</i> , 2022, 12, 210318.	1.5	12
1160	Postinjury platelet aggregation and venous thromboembolism. <i>Journal of Trauma and Acute Care Surgery</i> , 2022, 93, 604-612.	1.1	9
1168	Physiopathology and treatment of critical bleeding: a literature review. <i>Farmacia Hospitalaria</i> , 2015, 39, 382-90.	0.6	4
1169	Coagulation Management in Trauma: Do We Need a Viscoelastic Hemostatic Assay?. <i>Current Anesthesiology Reports</i> , 0, , 1.	0.9	0
1170	Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	35
1171	Coagulation factors XI and XII as possible targets for anticoagulant therapy. <i>Thrombosis Research</i> , 2022, 214, 53-62.	0.8	12
1172	Computational models of hemostasis: Degrees of complexity. <i>Applications in Engineering Science</i> , 2022, 10, 100103.	0.5	2
1173	Thromboelastography: a review for radiologists and implications on periprocedural bleeding risk. <i>Abdominal Radiology</i> , 2022, 47, 2697-2703.	1.0	5
1174	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. , 2013, , 332-397.		1
1175	Plasmatic coagulation profile after major traumatic injury: a prospective observational study. <i>European Journal of Trauma and Emergency Surgery</i> , 2022, 48, 4595-4606.	0.8	3
1176	Research Progress of Thrombolysis Diagram. <i>Advances in Clinical Medicine</i> , 2022, 12, 4414-4421.	0.0	0
1177	Thromboelastography and multiplate tests for current rotational left ventricular assist device management. <i>Journal of Cardiac Surgery</i> , 0, , .	0.3	0
1178	Proteomics of Coagulopathy Following Injury Reveals Limitations of Using Laboratory Assessment to Define Trauma-Induced Coagulopathy to Predict Massive Transfusion. <i>Annals of Surgery Open</i> , 2022, 3, e167.	0.7	2
1183	Haemostasis and Thrombosis. Spatial Organization of the Biochemical Processes at Microscale. <i>Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology</i> , 2022, 16, 107-114.	0.3	1
1184	A Novel Phenotype of the Factor 5 Gene Mutation (Homozygote Met1736Val and Heterozygote Asp68His) Is Associated With Moderate Factor V Deficiency. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
1185	IUA position statement on perioperative drug and hemostasis management in vascular surgery. <i>International Angiology</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
1186	A novel synthesised sulphonylhydrazone coumarin (E)-4-methyl-1-(1-(3-hydroxyphenyl)benzo[f]chromen-2-yl)ethanone in rats by attenuating oxidative damage, biological changes and electrocardiogram. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2022, 49, 1010-1026.	0.9	3
1187	Venous Thromboembolism in Sepsis: From Bench to Bedside. <i>Biomedicines</i> , 2022, 10, 1651.	1.4	5
1188	Modifications to Polysaccharide Polyelectrolyte Multilayers: Improved Mechanical Stability and Hemocompatibility. <i>ACS Applied Polymer Materials</i> , 2022, 4, 5975-5987.	2.0	0
1189	Comparison of assessment of coagulation in healthy dogs by the TEG 6s and TEG 5000 viscoelastic analyzers. <i>Journal of Veterinary Diagnostic Investigation</i> , 0, , 104063872211126.	0.5	0
1190	The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8283.	1.8	24
1191	Platelet Transfusion for Trauma Resuscitation. <i>Current Trauma Reports</i> , 2022, 8, 147-159.	0.6	1
1192	Risks of thrombosis: genotype and phenotype of blood coagulation factor V. , 2022, 2, 35-42.		1
1193	Advancing in the understanding of coagulopathy during hemorrhagic shock: From the triad to the deadly pentad. <i>Colombian Journal of Anesthesiology</i> , 0, , .	0.5	0
1194	Molecular View into Preferential Binding of the Factor VII Gla Domain to Phosphatidic Acid. <i>Biochemistry</i> , 2022, 61, 1694-1703.	1.2	2
1195	Trauma-induced coagulopathy management. <i>AboutOpen</i> , 0, 9, 77-82.	0.2	0
1196	Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders. <i>Journal of Clinical Medicine</i> , 2022, 11, 4932.	1.0	14
1197	Coagulation and complement: Key innate defense participants in a seamless web. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
1198	Platelet-Inspired Intravenous Nanomedicine for Injury-Targeted Direct Delivery of Thrombin to Augment Hemostasis in Coagulopathies. <i>ACS Nano</i> , 2022, 16, 16292-16313.	7.3	16
1199	Disorders of Hemostasis and Thrombosis. , 2023, , 173-211.		0
1200	Overview of Blood Coagulation and the Pathophysiology of Blood Coagulation Disorders. , 2022, , .		0
1201	Novel Antithrombotic Agents in Pregnancy Anticoagulants and Antiplatelet Agents. <i>Clinical Obstetrics and Gynecology</i> , 0, Publish Ahead of Print, .	0.6	0
1202	Reference intervals for platelet large cell ratio, platelet distribution width, plateletcrit and standard haematological parameters determined on the Sysmex XN-10 in a cohort of 30,917 Danish blood donors. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2022, 82, 439-445.	0.6	0
1203	Role of Viscoelastic and Conventional Coagulation Tests for Management of Blood Product Replacement in the Bleeding Patient. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	1.5	2

#	ARTICLE	IF	CITATIONS
1204	Advances in the Management of Coagulopathy in Trauma: The Role of Viscoelastic Hemostatic Assays across All Phases of Trauma Care. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 796-807.	1.5	3
1205	Viscoelastic Testing in the Management of Adult Patients on Mechanical Circulatory Support Devices with Focus on Extracorporeal Membrane Oxygenation. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	1.5	6
1206	A current view of sepsis-induced disseminated intravascular coagulation. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2022, 33, 526-534.	0.1	0
1207	Anesthetic Management of a Large Right Ventricular Mass due to Idiopathic Hypereosinophilic Syndrome in a Patient Undergoing Cardiac Surgery, a Case Report. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 0, , 108925322211329.	0.4	0
1208	Fibrinolysis Shutdown and Hypofibrinolysis Are Not Synonymous Terms: The Clinical Significance of Differentiating Low Fibrinolytic States. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 433-443.	1.5	4
1209	Viscoelastic Management of Coagulopathy during the Perioperative Period of Liver Transplantation. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	1.5	1
1210	EVALUATION OF THE HUMAN BLOOD PLATELETS SENSITIVITY TO AN ACTIVATION AGONIST ADENOSINE DIPHOSPHATE BY SCANNING FLOW CYTOMETRY UNDER CONDITIONS OF ANTIPLATELET THERAPY. , 2022, 7, 286-292.		0
1211	Investigating RNAâ€protein recognition mechanisms through supervised molecular dynamics (SuMD) simulations. <i>NAR Genomics and Bioinformatics</i> , 2022, 4, .	1.5	6
1212	Identification of nonâ€neutralizing antiâ€factor X autoantibodies in three Japanese cases of autoimmune acquired factor X deficiency. <i>Haemophilia</i> , 2023, 29, 555-563.	1.0	3
1214	Individualized Management of Coagulopathy in Patients with End-Stage Liver Disease. <i>Diagnostics</i> , 2022, 12, 3172.	1.3	0
1215	Development and verification of a novel blood viscoelastic monitoring method based on reciprocating motion of magnetic bead. <i>Biomedizinische Technik</i> , 2022, .	0.9	0
1216	Improvement of halitosis by probiotic bacterium <i>Weissella cibaria</i> CMU: A randomized controlled trial. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	6
1217	Thrombin generation and implications for hemophilia therapies: A narrative review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100018.	1.0	2
1218	A novel mouse whole blood thrombin generation assay sensitive to FXI- and FIX-mediated amplification of coagulation. <i>Blood Advances</i> , 0, , .	2.5	2
1219	Tissue repair. , 2024, , 115-121.		1
1220	Pharmacology and Clinical Development of Factor XI Inhibitors. <i>Circulation</i> , 2023, 147, 897-913.	1.6	37
1221	Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on the Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1381-1384.	1.9	3
1222	Pharmacology of Heparin and Related Drugs: An Update. <i>Pharmacological Reviews</i> , 2023, 75, 328-379.	7.1	16

#	ARTICLE	IF	CITATIONS
1223	Haemophilia A: A Review of Clinical Manifestations, Treatment, Mutations, and the Development of Inhibitors. <i>Hematology Reports</i> , 2023, 15, 130-150.	0.3	0
1224	An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation. <i>Cells</i> , 2023, 12, 778.	1.8	6
1225	Approach to thromboelastography-based transfusion in cirrhosis: An alternative perspective on coagulation disorders. <i>World Journal of Gastroenterology</i> , 0, 29, 1460-1474.	1.4	1
1226	Perioperative Coagulation Monitoring in Congenital Heart Disease Patients. , 2023, , 287-312.		0
1227	Biochemical, hematological, peripheral smear and weight evaluation of low dose Epigallocatechin Gallate in Diethylnitrosamine administered rats. <i>Journal of Contemporary Medicine</i> , 2023, 13, 365-370.	0.1	0
1228	D-Dimer Levels, Stroke, and Critical Care. <i>Biomarkers in Disease</i> , 2023, , 501-524.	0.0	0
1229	Hematology and Coagulation Disorders. , 2017, , 1142-1168.e6.		0
1230	Involvement of monocyte-derived extracellular vesicle-associated tissue factor activity in convallatoxin-induced hypercoagulability. <i>Blood Coagulation and Fibrinolysis</i> , 2023, 34, 184-190.	0.5	0
1231	HÄmostase. <i>Springer Reference Medizin</i> , 2023, , 1-34.	0.0	0
1232	Perioperative Management of a Patient with Hemophilia C and Allergy to Fresh Frozen Plasma. <i>Case Reports in Anesthesiology</i> , 2023, 2023, 1-4.	0.2	0
1233	Etiology and management of hypofibrinogenemia in trauma. <i>Current Opinion in Anaesthesiology</i> , 2023, 36, 382-387.	0.9	1
1234	Haematological Trends and Transfusion during Adult Extracorporeal Membrane Oxygenation: A Single Centre Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 2629.	1.0	1
1235	Pathophysiological, immunogenetic, anatomopathological profile of thrombophilia in pregnancy. <i>Transfusion Clinique Et Biologique</i> , 2023, 30, 360-367.	0.2	0
1240	The Quantra System: System Description and Protocols for Measurements. <i>Methods in Molecular Biology</i> , 2023, , 743-761.	0.4	6
1242	Coagulation and Thrombosis. , 2023, , 107-125.		0
1249	Coagulopathy in the ICU. , 2023, , 608-614.		0
1283	Disorders of Blood, Coagulation, and Bone Marrow. , 2024, , 332-366.		0